المؤلفون: S. V. Popov, R. G. Huseynov, E. V. Pomeshkin, O. N. Scriabin, K. V. Sivak, V. V. Perepelitsa, T. A. Lelyavina, E. A. Malyshev, С. В. Попов, Р. Г. Гусейнов, Е. В. Помешкин, О. Н. Скрябин, К. В. Сивак, В. В. Перепелица, Т. А. Лелявина, Е. А. Малышев

المصدر: Urology Herald; Том 12, № 3 (2024); 70-78 ; Вестник урологии; Том 12, № 3 (2024); 70-78 ; 2308-6424 ; 10.21886/2308-6424-2024-12-3

مصطلحات موضوعية: мочевой пузырь, transurethral resection of the bladder, laser resection, recurrence, bladder, трансуретральная резекция мочевого пузыря, лазерная резекция, рецидив

وصف الملف: application/pdf

Relation: https://www.urovest.ru/jour/article/view/884/564; Гусниев М.А., Печникова В.В., Гущин М.Ю., Гусниев С.А., Гиоева З.В., Пшихачев А.М., Михалева Л.М. Анализ факторов риска рецидива немышечно-инвазивного рака мочевого пузыря после его комбинированного лечения. Медицинский вестник Северного Кавказа. 2022;17(3):264-268. DOI:10.14300/mnnc.2022.17064; Shore ND, Palou Redorta J, Robert G, Hutson TE, Cesari R, Hariharan S, Rodríguez Faba Ó, Briganti A, Steinberg GD. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. Urol Oncol. 2021;39(10):642-663. DOI:10.1016/j.urolonc.2021.05.015; Иванов С.А., Заборский И.Н., Чайков В.С. Лечение немышечно-инвазивного рака мочевого пузыря высокого риска. Вестник урологии. 2017;5(2):42-49. DOI:10.21886/2308-6424-2017-5-2-42-49; Al Hussein Al Awamlh B, Chang SS. Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. Curr Oncol Rep. 2023;25(2):83-91. DOI:10.1007/s11912-022-01350-9; Бабаевская Д.И., Базаркин А.К., Тараткин М.С., Еникеев Д.В. Новейшие достижения в трансуретральной резекции стенки мочевого пузыря с опухолью. Вестник урологии. 2022;10(1):96-103. DOI:10.21886/2308-6424-2022-10-1-96-103; Ивахно К.Ю., Важенин А.В., Карнаух П.А., Мисюкевич Н.Д. Мировой опыт применение тулиевого лазера в лечении мышечно-неинвазивного рака мочевого пузыря. Вестник Совета молодых учёных и специалистов Челябинской области. 2018;2(1):111-112. eLIBRARY ID: 35010553; EDN: XOXQBV; Li C, Gao L, Zhang J, Yang X, Liu C. The effect of holmium laser resection versus standard transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Lasers Med Sci. 2020;35(5):1025-1034. DOI:10.1007/s10103-020-02972-w; Chen J, Zhao Y, Wang S, Jin X, Sun P, Zhang L, Wang M. Green-light laser en bloc resection for primary non-muscle-invasive bladder tumor versus transurethral electroresection: A prospective, nonrandomized two-center trial with 36-month follow-up. Lasers Surg Med. 2016;48(9):859-865. DOI:10.1002/lsm.22565; Xu Y, Guan W, Chen W, Xie C, Ouyang Y, Wu Y, Liu C. Comparing the treatment outcomes of potassium-titanyl-phosphate laser vaporization and transurethral electroresection for primary nonmuscle-invasive bladder cancer: A prospective, randomized study. Lasers Surg Med. 2015;47(4):306-311. DOI:10.1002/lsm.22342; Jin YH, Zeng XT, Liu TZ, Bai ZM, Dou ZL, Ding DG, Fan ZL, Han P, Huang YR, Huang X, Li M, Li XD, Li YN, Li XH, Liang CZ, Liu JM, Ma HS, Qi J, Shi JQ, Wang J, Wang DL, Wang ZP, Wang YY, Wang YB, Wei Q, Xia HB, Xing JC, Yan SY, Zhang XP, Zheng GY, Xing NZ, He DL, Wang XH; Chinese Urological Doctor Association (CUDA), Urological Association of Chinese Research Hospital Association (CRHA-UA), Uro-Health Promotive Association of China International Exchange, Promotive Association for Medical, Health Care (CPAM-UHPA). Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res. 2022;9(1):44. DOI:10.1186/s40779-022-00406-y; Musat MG, Kwon CS, Masters E, Sikirica S, Pijush DB, Forsythe A. Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR). Clinicoecon Outcomes Res. 2022;14:35-48. DOI:10.2147/CEOR.S341896; Liem EIML, Freund JE, Savci-Heijink CD, de la Rosette JJMCH, Kamphuis GM, Baard J, Liao JC, van Leeuwen TG, de Reijke TM, de Bruin DM. Validation of Confocal Laser Endomicroscopy Features of Bladder Cancer: The Next Step Towards Real-time Histologic Grading. Eur Urol Focus. 2020;6(1):81-87. DOI:10.1016/j.euf.2018.07.012; Poletajew S, Krajewski W, Gajewska D, Sondka-Migdalska J, Borowik M, Buraczyński P, Dzięgała M, Łykowski M, Przudzik M, Tukiendorf A, Woźniak R, Bar K, Jabłonowski Z, Roslan M, Słojewski M, Zdrojowy R, Radziszewski P, Dziobek K. Prediction of the risk of surgical complications in patients undergoing monopolar transurethral resection of bladder tumour - a prospective multicentre observational study. Arch Med Sci. 2019;16(4):863-870. DOI:10.5114/aoms.2019.88430; Kamadjou C, Kuitche J, Wadeu A, Mbassi A, Angwafo F. Transurethral Resection of Bladder Tumours: Results and Outcomes. Open Journal of Urology. 2022;12:342-356. DOI:10.4236/oju.2022.126033; Lonati C, Esperto F, Scarpa RM, Papalia R, Gómez Rivas J, Alvarez-Maestro M, Afferi L, Fankhauser CD, Mattei A, Colombo R, Montorsi F, Briganti A, Krajewski W, Carando R, Laukhtina E, Teo JY, Zamboni S, Simeone C, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YA U): Urothelial Carcinoma Working Group; European Association of Urology - European Society of Resident Urologists (EAU-ESRU). Bladder perforation during transurethral resection of the bladder: a comprehensive algorithm for diagnosis, management and follow-up. Minerva Urol Nephrol. 2022;74(5):570-580. DOI:10.23736/S2724-6051.21.04436-0; Long G, Zhang Y, Sun G, Ouyang W, Liu Z, Li H. Safety and efficacy of thulium laser resection of bladder tumors versus transurethral resection of bladder tumors: a systematic review and meta-analysis. Lasers Med Sci. 2021;36(9):1807-1816. DOI:10.1007/s10103-021-03272-7; https://www.urovest.ru/jour/article/view/884

الاتاحة: https://www.urovest.ru/jour/article/view/884
https://doi.org/10.21886/2308-6424-2024-12-3-70-78

المؤلفون: K. V. Sivak, K. I. Stosman, E. Yu. Kalinina, M. M. Lyubishin, Ya. R. Orshanskaya, T. N. Savateeva-Lyubimova, S. B. Kazakova, D. M. Fedoseeva, A. S. Nazarov, E. I. Radion, S. M. Yudin, A. A. Keskinov, V. V. Makarov, V. S. Yudin, A. O. Zheltukhin, P. O. Vorobyev, D. V. Kochetkov, G. V. Ilyinskaya, A. V. Lipatova, P. M. Chumakov, К. В. Сивак, К. И. Стосман, Е. Ю. Калинина, М. М. Любишин, Я. Р. Оршанская, Т. Н. Саватеева-Любимова, С. Б. Казакова, Д. М. Федосеева, А. С. Назаров, Е. И. Радион, С. М. Юдин, А. А. Кескинов, В. В. Макаров, В. С. Юдин, А. О. Желтухин, П. О. Воробьев, Д. В. Кочетков, Г. В. Ильинская, А. В. Липатова, П. М. Чумаков

المساهمون: Исследование проводилось при финансовой поддержке ФГБУ «ЦСП» ФМБА России, договор № 037310012210000079 от 03.11.2020 «Доклиническое изучение общетоксического, местнораздражающего действия, фармакологической безопасности, пирогенности, иммунотоксичности и аллергизирующих свойств препаратов из штаммов непатогенных онколитических вирусов».

المصدر: Safety and Risk of Pharmacotherapy; 2024: Online First ; Безопасность и риск фармакотерапии; 2024: Online First ; 2619-1164 ; 2312-7821 ; undefined

مصطلحات موضوعية: доклиническое исследование, enteroviruses, oncolytic viruses, oncolytic strains, safety pharmacology, toxicity, rats, mice, rabbits, preclinical study, энтеровирусы, онколитические вирусы, онколитические штаммы, фармакологическая безопасность, токсичность, крысы, мыши, кролики

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/415/1091; https://www.risksafety.ru/jour/article/view/415/1094; https://www.risksafety.ru/jour/article/view/415/1103; https://www.risksafety.ru/jour/article/view/415/1104; https://www.risksafety.ru/jour/article/view/415/1112; https://www.risksafety.ru/jour/article/view/415/1120; https://www.risksafety.ru/jour/article/view/415/1124; https://www.risksafety.ru/jour/article/view/415/1127; https://www.risksafety.ru/jour/article/view/415/1131; https://www.risksafety.ru/jour/article/view/415/1134; https://www.risksafety.ru/jour/article/downloadSuppFile/415/445; https://www.risksafety.ru/jour/article/downloadSuppFile/415/446; https://www.risksafety.ru/jour/article/downloadSuppFile/415/487; https://www.risksafety.ru/jour/article/downloadSuppFile/415/488; https://www.risksafety.ru/jour/article/downloadSuppFile/415/489; https://www.risksafety.ru/jour/article/downloadSuppFile/415/490; https://www.risksafety.ru/jour/article/downloadSuppFile/415/506; Глухов АИ, Сивохин ДА, Серяк ДА, Родионова ТС, Камынина МИ. Онколитические вирусы как иммунотерапевтические агенты в лечении злокачественных новообразований. Вестник РАМН. 2019;74(2):108–17. https://doi.org/10.15690/vramn1091; de la Nava D, Selvi KM, Alonso MM. Immunovirotherapy for pediatric solid tumors: a promising treatment that is becoming a reality. Front Immunol. 2022;13:866892. https://doi.org/10.3389/fimmu.2022.866892; Воробьева ИВ, Жирнов ОП. Современные подходы к лечению рака онколитическими вирусами. Microbiology Independent Research Journal. 2022;9(1):91–112. https://doi.org/10.18527/2500-2236-2022-9-1-91-112; Чернякова АП, Бороздина СА. Механизмы действия и клинические эффекты препаратов онколитических аденовирусов, герпесвирусов, реовирусов и вируса кори. Juvenis Scientia. 2020;6(6):6–17. https://doi.org/10.32415/jscientia_2020_6_6_6-17; Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal TranSDuct Target Ther. 2023;8(1):156. https://doi:10.1038/s41392-023-01407-6; Yang L, Gu X, Yu J, Ge Sh, Fan X. Oncolytic virotherapy: from bench to bedside front. Cell Dev Biol. 2021;9:790150. https://doi.org/10.3389/fcell.2021.790150; Ramelyte E, Tastanova A, Balázs Z, Ignatova D, Turko P, Menzel U, et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer Cell. 2021;39(3):394–406.e4. https://doi.org/10.1016/j.ccell.2020.12.022; Russell SJ, Bell JC, Engeland CE, McFadden G. Advances in oncolytic virotherapy. Commun Med (Lond). 2022;2:33. https://doi.org/10.1038/s43856-022-00098-4; Чумаков ПМ. Обеспечат ли онколитические вирусы революцию в онкологии? Вестник РАН. 2019;89(5):475–84. https://doi.org/10.31857/S0869-5873895475-484; Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160–77. https://doi.org/10.1038/s41571-022-00719-w; Rahman MM, McFadden G. Oncolytic viruses: newest frontier for cancer immunotherapy. Cancers (Basel). 2021;13(21):5452. https://doi.org/10.3390/cancers13215452; Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18(8):498–513. https://doi.org/10.1038/s41577-018-0014-6; Malogolovkin A, Gasanov N, Egorov A, Weener M, Ivanov R, Karabelsky A. Combinatorial approaches for cancer treatment using oncolytic viruses: projecting the perspectives through clinical trials outcomes. Viruses. 2021;13:1271. https://doi.org/10.3390/v13071271; McCarthy C, Jayawardena N, Burga LN, Bostina M. Developing picornaviruses for cancer therapy. Cancers. 2019;11:685. https://doi.org/10.3390/cancers11050685; Леa ТХ, Липатова АВ, Вольская МА, Тихонова ОА, Чумаков ПМ. Состояние сигнального пути JAK/STAT влияет на чувствительность опухолевых клеток к онколитическим энтеровирусам. Молекулярная биология. 2020;54(4):634–42. https://doi.org/10.31857/S0026898420040102; Ворошилова МК. Энтеровирусные инфекции человека. М.: Медицина; 1979.; Чумаков МП, Ворошилова МК, Анцупова АС, Бойко ВМ, Блинова МИ, Приймяги ЛС и др. Живые энтеровирусные вакцины для экстренной профилактики массовых респираторных заболеваний во время осенне-зимних эпидемий гриппа и острых респираторных заболеваний. Журнал микробиологии, эпидемиологии и иммунобиологии. 1992;69(11–12):37–40. EDN: ZXJVLF; Нетесов СВ, Кочнева ГВ, Локтев ВБ, Святченко ВА, Сергеев АН, Терновой ВА и др. Онколитические вирусы: достижения и проблемы. Медицинский алфавит. Эпидемиология и санитария. 2011;(3):26–33. EDN: OXGJHP; Ворошилова МК. Вирусологические и иммунологические аспекты применения ЖЭВ при онкологических заболеваниях. В кн.: Полезные для организма непатогенные штаммы энтеровирусов: профилактическое и лечебное их применение. М.: Изд-во Минздрава СССР; 1988. С. 24–9.; Чумаков ПМ, Морозова ВВ, Бабкин ИВ, Байков ИК, Нетесов СВ, Тикунова НВ. Онколитические энтеровирусы. Молекулярная биология. 2012;46(5):712–25. https://doi.org/10.1134/S0026893312050032; Клаан НК, Акиньшина ЛП, Пронина ТА. Онколитические вирусы в терапии злокачественных новообразований. Российский биотерапевтический журнал. 2018;17(4):6–19. https://doi.org/10.17650/1726-9784-2018-17-4-6-19; Chiu M, Armstrong EJL, Jennings V, Foo S, Crespo-Rodriguez E, Bozhanova G, et al. Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert Opin Biol Ther. 2020;20(6):635–52. https://doi.org/10.1080/14712598.2020.1729351; Martin NT, Bell JC. Oncolytic virus combination therapy: killing one bird with two stones. Mol Ther. 2018;26(6):1414–22. https://doi.org/10.1016/j.ymthe.2018.04.001; Ghonime MG, Cassady KA. Combination therapy using ruxolitinib and oncolytic HSV renders resistant MPNSTs susceptible to virotherapy. Cancer Immunol Res. 2018;6(12):1499–510. https://doi.org/10.1158/2326-6066; Tanaka R, Goshima F, Esaki S, Sato Y, Murata T, Nishiyama Y, et al. The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model. Am J Cancer Res. 2017;7(8):1693–703. PMID: 28861325; O’Donoghue C, Doepker MP, Zager JS. Talimogene laherparepvec: overview, combination therapy and current practices. Melanoma Manag. 2016;3(4):267–72. https://doi.org/10.2217/mmt-2016-002; Zhang S, ed. Progress in cancer immunotherapy. Springer; 2016. https://doi.org/10.1007/978-94-017-7555-7; Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2(4):295–300. https://doi.org/10.1158/2326-6066.CIR-14-0015; Shakiba Y, Vorobyev PO, Mahmoud M, Hamad A, Kochetkov DV, Yusubalieva GM, et al. Recombinant strains of oncolytic vaccinia virus for cancer immunotherapy. Biochemistry (Mosc). 2023;88(6):823–41. https://doi.org/10.1134/S000629792306010X; Lal G, Rajala MS. Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy. Cancer Gene Ther. 2018;25(9–10):216–26. https://doi.org/10.1038/s41417-018-0018-1; Gromeier M, Nair SK. Recombinant poliovirus for cancer immunotherapy. Annu Rev Med. 2018;69:289–99. https://doi.org/10.1146/annurev-med-050715-104655; Voroshilova MK. Interferon-producing enterovirus vaccines (Live enterovirus vaccines, their interfering and interferonogenic activity and their use for prophylaxis of enteroviral and respiratory infections). Crit Rev Clin Lab Sci. 1970;117–8.; Voroshilova MK. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol. 1989;36:191–202. PMID: 2555836; Ворошилова МК, Магазаник СС, Чумаков ПМ. Полезные вирусы человека. Актуальные вопросы эпидемиологии, микробиологии и инфекционных заболеваний. Ташкент: Медицина; 1980.; Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci USA. 1996;93(6):2370–5. https://doi.org/10.1073/pnas.93.6.2370; Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA. 2000;97(12):6803–8. . https://doi.org/10.1073/pnas.97.12.6803; Soboleva AV, Seryak DA, Gabdrakhmanova AF, Sosnovtseva AO, Le TH, Kochetkov DV, et al. Glioblastoma multiforme stem cells are highly sensitive to some human non-pathogenic enteroviruses. J Pharm Sci Res. 2018:10(4):936–9. https://doi.org/10.5281/zenodo.1285619; Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3(6):841–49. https://doi.org/10.1001/jamaoncol.2016.2064; Pol J, Buque A, Aranda F, Bloy N, Cremer I, Eggermont A, et al. Trial watch — oncolytic viruses and cancer therapy. Oncoimmunology. 2016;5(2):e1117740. https://doi.org/10.1080/2162402x.2015.1117740; Warner SG, O’Leary MP, Fong Y. Therapeutic oncolytic viruses: clinical advances and future directions. Curr Opin Oncol. 2017;29(5):359–65. https://doi.org/10.1097/cco.0000000000000388; Jia Y, Miyamoto S, Soda Y, Takishima Y, Sagara M, Liao J, et al. Extremely low organ toxicity and strong antitumor activity of miR-34-regulated oncolytic coxsackievirus B3. Mol Ther Oncolytics. 2019;12:246–58. https://doi.org/10.1016/j.omto.2019.01.003; Sakamoto A, Inoue H, Miyamoto S, Ito S, Soda Y, Tani K. Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer. Sci Rep. 2023;13(1):5924. https://doi.org/10.1038/s41598-023-33126-x; Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal TranSDuct Target Ther. 2023;8(1):156. https://doi.org/10.1038/s41392-023-01407-6; https://www.risksafety.ru/jour/article/view/415

الاتاحة: https://www.risksafety.ru/jour/article/view/415
https://doi.org/10.30895/2312-7821-2024-415

المؤلفون: S. V. Popov, R. G. Guseynov, I. N. Isakova-Sivak, K. V. Sivak, O. N. Skryabin, V. V. Perepelitsa, D. I. Sengirbaev, N. S. Bunenkov, P. G. Osipov, T. A. Lelyavina, С. В. Попов, Р. Г. Гусейнов, И. Н. Исакова-Сивак, К. В. Сивак, О. Н. Скрябин, В. В. Перепелица, Д. И. Сенгирбаев, Н. С. Буненков, П. Г. Осипов, Т. А. Лелявина

المصدر: Cancer Urology; Том 20, № 1 (2024); 164-173 ; Онкоурология; Том 20, № 1 (2024); 164-173 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: профилактика, bladder cancer, prostate cancer, thromboembolism, morbidity, risk factor, prevention, рак мочевого пузыря, рак предстательной железы, тромбоэмболия, заболеваемость, фактор риска

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1702/1527; Cornejo K.M., Rice-Stitt T., Wu C.L. Updates in staging and reporting of genitourinary malignancies. Arch Pathol Lab Med 2020;144(3):305–19. DOI:10.5858/arpa.2019-0544-RA; Netto G.J., Amin M.B., Berney D.M. et al. The 2022 World Health Organization Classification of tumors of the urinary system and male genital organs – part B: prostate and urinary tract tumors. Eur Urol 2022;82(5):469–82. DOI:10.1016/j.eururo.2022.07.002; Williams S.B., Ray-Zack M.D., Hudgins H.K. et al. Impact of centralizing care for genitourinary malignancies to high-volume providers: a systematic review. Eur Urol Oncol 2019;2(3):265–73. DOI:10.1016/j.euo.2018.10.006; Somov A.N., Suslin S.A. Prostate cancer. Epidemiology, risk factors and early detection. Profilakticheskaya meditsina = The Russian Journal of Preventive Medicine 2020;23(3):149–55. (In Russ.). DOI:10.17116/profmed202023031149; Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. DOI:10.3322/caac.21660; Malignant tumors in Russia in 2021 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 252 p. (In Russ.).; Somonova O.V., Elizarova A.L., Borisenko N.N., Kornushenko U.A. Thrombosis in an oncological patient and cancer in a patient with thrombosis: What to do? Zlokachestvennye opukholi = Malignant Tumors 2018;(3s1):110–4. (In Russ.). DOI:10.18027/2224-5057-2018-8-3s1-110-114; Shah S., Karathanasi A., Revythis A. et al. Cancer-associated thrombosis: a new light on an old story. Diseases 2021;9(2):34. DOI:10.3390/diseases9020034; Mahajan A., Brunson A., Adesina O. et al. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv 2022;6(1):307–20. DOI:10.1182/bloodadvances.2021005590; Mukai M., Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol 2018;72(2):89–93. DOI:10.1016/j.jjcc.2018.02.011; Mulder F.I., Horváth-Puhó E., van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021;137(14):1959–69. DOI:10.1182/blood.2020007338; Rozenko D.A., Ushakova N.D., Tikhonova S.N. et al. Effective use of extracorporeal membrane oxygenation in surgical treatment of kidney cancer patient with tumor thrombosis. Yuzhno-Rossiyskiy onkologicheskiy zhurnal = South Russian Journal of Cancer 2022;3(3):32–40. (In Russ.). DOI:10.37748/2686-9039-2022-3-3-4; Fernandes C.J., Morinaga L.T.K., Alves J.L. Jr et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev 2019;28(151):180119. DOI:10.1183/16000617.0119-2018; Navi B.B., Reiner A.S., Kamel H. et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 2019;133(8):781–9. DOI:10.1182/blood-2018-06-860874; Petrov V.I., Gorbatenko V.S., Shatalova O.V., Gerasimenko A.S. Venous thromboembolic complications in oncological patients: Etiopathogenesis and prevention. Lekarstvenniy vestnik = Drug Bulletin 2020;14(3):16–22. (In Russ.).; Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood 2019;134(22):1912–8. DOI:10.1182/blood.2019001388; Kim A.S., Khorana A.A., McCrae K.R. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res 2020;225:33–53. DOI:10.1016/j.trsl.2020.06.012; Costa J., Araújo A. Cancer-related venous thromboembolism: from pathogenesis to risk assessment. Semin Thromb Hemost 2021;47(6):669–76. DOI:10.1055/s-0040-1718926; Khorana A.A., Mackman N., Falanga A. et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers 2022;8(1):11. DOI:10.1038/s41572-022-00336-y; Chuang L.H., Gumbs P., van Hout B. et al. Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. Qual Life Res 2019;28(8):2111–24. DOI:10.1007/s11136-019-02175-z; Suzuki-Inoue K. Roles of the CLEC-2-podoplanin interaction in tumor progression. Platelets 2018:1–7. DOI:10.1080/09537104.2018.1478401; Frere C., Benzidia I., Marjanovic Z., Farge D. Recent advances in the management of cancer-associated thrombosis: new hopes but new challenges. Cancers (Basel) 2019;11(1):71. DOI:10.3390/cancers11010071; Raskob G.E., van Es N., Verhamme P. et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378(7):615–24. DOI:10.1056/NEJMoa1711948; Glise Sandblad K., Hansson P.O., Philipson J. et al. Prevalence of cancer in patients with venous thromboembolism: a retrospective nationwide case–control study in Sweden. Clin Appl Thromb Hemost 2023;29:10760296231158368. DOI:10.1177/10760296231158368; Park H., Jeong C.W., Yuk H. et al. Influence of tumor thrombus on occurrence of distant venous thromboembolism and survival in patients with renal cell carcinoma after surgery. Clin Appl Thromb Hemost 2019;25:1076029618823288. DOI:10.1177/1076029618823288; Streiff M.B., Holmstrom B., Angelini D. et al. NCCN Clinical Practice Guidelines in Oncology: cancer-associated venous thromboembolic disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19(10):1181–201. DOI:10.6004/jnccn.2021.0047; Lyman G.H., Carrier M., Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021;5(4):927–74. DOI:10.1182/bloodadvances.2020003442; Guman N.A.M., van Geffen R.J., Mulder F.I. et al. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer. J Thromb Haemost 2021;19(12):2974–83. DOI:10.1111/jth.15503; Abdullah O., Parashar D., Mustafa I.J., Young A.M. Venous thromboembolism rate in patients with bladder cancer according to the type of treatment: a systematic review. Cureus 2022;14(3):e22945. DOI:10.7759/cureus.22945; Ibragimova N.Sh., Usupova M.A. Risk factors of venous thromboembolic complications in oncological surgery. Avitsenna = Avicenna 2020;66:17–9. (In Russ.).; Slukhanchuk E.V., Bitsadze V.O., Tyan A.G. et al. Thrombosis risk factors in oncological patients. Vestnik RAMN = Annals of the Russian Academy of Medical Sciences 2021;76(5):465–75. (In Russ.). DOI:10.15690/vramn1459; Pabinger I., van Es N., Heinze G. et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018;5(7):e289–98. DOI:10.1016/S2352-3026(18)30063-2; Sevestre M.A., Soudet S. Epidemiology and risk factors for cancer-associated thrombosis. J Med Vasc 2020;45(6S):6S3–7. DOI:10.1016/S2542-4513(20)30513-7; Klaassen Z., Wallis C.J.D., Lavallée L.T., Violette P.D. Perioperative venous thromboembolism prophylaxis in prostate cancer surgery. World J Urol 2020;38(3):593–600. DOI:10.1007/s00345-019-02705-x; Meguro S., Kataoka M., Endo Y.U. et al. Low risk of venous thromboembolism after robot-assisted radical prostatectomy through systemic image assessment: a prospective study. In Vivo 2022;36(5):2384–91. DOI:10.21873/invivo.12971; Klaassen Z., Arora K., Goldberg H. et al. Extended venous thromboembolism prophylaxis after radical cystectomy: a call for adherence to current guidelines. J Urol 2018;199(4):906–14. DOI:10.1016/j.juro.2017.08.130; Ottosson K., Pelander S., Johansson M. et al. The increased risk for thromboembolism pre-cystectomy in patients undergoing neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer is mainly due to central venous access: a multicenter evaluation. Int Urol Nephrol 2020;52(4):661–9. DOI:10.1007/s11255-019-02338-4.; Korotaeva A.A., Apanovich N.V., Braga E.A. et al. Current advances in kidney cancer immunotherapy. Onkourologiya = Cancer Urology 2019;15(4):30–8. (In Russ.). DOI:10.17650/1726-9776-2019-15-4-30-38; Moiseenko F.V. Future of systemic therapy in oncourology: targeted and immunotherapy. Prakticheskaya onkologiya = Practical Oncology 2019;20(2):137–43. (In Russ.).; Moik F., Chan W.E., Wiedemann S. et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 2021;137(12):1669–78. DOI:10.1182/blood.2020007878; Kacimi S.E.O., Moeinafshar A., Haghighi S.S. et al. Venous thromboembolism in cancer and cancer immunotherapy. Crit Rev Oncol Hematol 2022;178:103782. DOI:10.1016/j.critrevonc.2022.103782; Kartolo A., Yeung C., Moffat G.T. et al. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors. Immunotherapy 2022;14(1):23–30. DOI:10.2217/imt-2021-0151; Sheng I.Y., Gupta S., Reddy C.A. et al. Thromboembolism in patients with metastatic renal cell carcinoma treated with immunotherapy. Target Oncol 2021;16(6):813–21. DOI:10.1007/s11523-021-00852-z; Di Nisio M., van Es N., Rotunno L. et al. Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. J Thromb Thrombolysis 2019;48(1):125–33. DOI:10.1007/s11239-019-01845-6; Volkova M.I., Vashakmadze N.L., Klimov A.V. et al. Prognosis of patients operated on for renal cell carcinoma and tumor venous thrombosis: experience of the Urology Clinics, N.N. Blokhin National Medical Research Center of Oncology. Onkourologiya = Cancer Urology 2021;17(3):19–28. (In Russ.). DOI:10.17650/1726-9776-2021-17-3-19-28; Garas S.N., McAlpine K., Ross J. et al. Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer. Urol Oncol 2022;40(8):381.e1–7. DOI:10.1016/j.urolonc.2022.04.006; Van Es N., Ventresca M., Di Nisio M. et al. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. J Thromb Haemost 2020;18(8):1940–51. DOI:10.1111/jth.14824; Iqbal U., Elsayed A.S., Ozair S. et al. Validation of the Khorana score for prediction of venous thromboembolism after robot-assisted radical cystectomy. J Endourol 2021;35(6):821–7. DOI:10.1089/end.2020.0800; Sushinskaya T.V., Stuklov N.I., Dobrokhotova Iu.E. Hemostasis and cancer-associated thrombosis: modern prevention and treatment. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2018;7(4):64–72. (In Russ.). DOI:10.17116/onkolog20187464; Elshoury A., Schaefer J.K., Lim M.Y. et al. Update on guidelines for the prevention of cancer-associated thrombosis. J Natl Compr Canc Netw 2022;20(13). DOI:10.6004/jnccn.2021.7108; Kahale L.A., Hakoum M.B., Tsolakian I.G. et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev 2018;6(6):CD006650. DOI:10.1002/14651858.CD006650.pub5; Rausa E., Kelly M.E., Asti E. et al. Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: systematic review and meta-analysis of randomized clinical trials. Surgery 2018;164(6):1234–40. DOI:10.1016/j.surg.2018.05.028; Bredikhin R.A., Akhmetzyanov R.V., Khayrullin N. Expanding the possibilities of treatment and prevention of venous thromboembolic complications in cancer patients. The role of oral anticoagulants. Klinitsist = The Clinician 2022;16(2):17–26. (In Russ.). DOI:10.17650/1818-8338-2022-16-2-К667; Mosarla R.C., Vaduganathan M., Qamar A. et al. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J Am Coll Cardiol 2019;73(11):1336–49. DOI:10.1016/j.jacc.2019.01.017; Guntupalli S.R., Brennecke A., Behbakht K. et al. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open 2020;3(6):e207410. DOI:10.1001/jamanetworkopen.2020.7410; Young A.M., Marshall A., Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36(20):2017–23. DOI:10.1200/JCO.2018.78.8034; Planquette B., Bertoletti L., Charles-Nelson A. et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 2022;161(3):781–90. DOI:10.1016/j.chest.2021.09.037; McBane R.D. 2nd, Wysokinski W.E., Le-Rademacher J.G. et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020;18(2):411–21. DOI:10.1111/jth.14662; Agnelli G., Becattini C., Meyer G. et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382(17):1599–607. DOI:10.1056/NEJMoa1915103; Mahé I., Agnelli G., Ay C. et al. Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT study. Thromb Haemost 2022;122(4):646–56. DOI:10.1055/a-1647-9896; Dai J.C., Morgan T.N., Kusin S. et al. Use of Pre-operative pharmacologic venous thromboembolism prophylaxis for robotic partial nephrectomy. Urology 2021;154:177–83. DOI:10.1016/j.urology.2021.03.043; Lapébie F.X., Bura-Rivière A., Espitia O. et al. Predictors of recurrence of cancer–associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study. J Thromb Haemost 2023:21(8):2189–201. DOI:10.1016/j.jtha.2023.04.010; Key N.S., Khorana A.A., Kuderer N.M. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020;38(5):496–520. DOI:10.1200/JCO.19.01461; Carrier M., Abou-Nassar K., Mallick R. et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019;380(8):711–9. DOI:10.1056/NEJMoa1814468; Khorana A.A., McNamara M.G., Kakkar A.K. et al. Assessing full benefit of rivaroxaban prophylaxis in high-risk ambulatory patients with cancer: thromboembolic events in the randomized CASSINI trial. TH Open 2020;4(2):e107–12. DOI:10.1055/s-0040-1712143; Agnelli G. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer. N Engl J Med 2019;380(8):781–3. DOI:10.1056/NEJMe1816060; Xin Z., Liu F., Du Y. et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients: a systematic review and network meta-analysis. Ann Palliat Med 2020;9(5):2970–81. DOI:10.21037/apm-20-47; Balabanova Y., Farahmand B., Stattin P. et al. Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden. BMC Urol 2022;22(1):15. DOI:10.1186/s12894-022-00967-z; Dall C.P., Shaw N., Egan J. et al. Practice patterns for extended venous thromboembolism chemoprophylaxis among urologic oncologists after radical cystectomy. Urol Oncol 2020;38(11):849.e19–23. DOI:10.1016/j.urolonc.2020.05.030; Prisco D., Tufano A., Cenci C. et al. Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. Intern Emerg Med 2019;14(1):21–38. DOI:10.1007/s11739-018-1956-1; Fedotkina Yu.A., Panchenko E.P. Modern approaches to the prevention of venous thromboembolic complications in patients with active cancer. Aterotromboz = Atherothrombosis 2022;12(2):44–62. (In Russ.) DOI:10.21518/2307-1109-2022-12-2-44-62; https://oncourology.abvpress.ru/oncur/article/view/1702

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1702
https://doi.org/10.17650/1726-9776-2024-20-1-164-173

المؤلفون: S. V. Popov, R. G. Guseynov, A. V. Vasin, K. V. Sivak, E. V. Pomeshkin, V. V. Perepelitsa, N. S. Bunenkov, T. A. Lelyavina, С. В. Попов, Р. Г. Гусейнов, А. В. Васин, К. В. Сивак, Е. В. Помешкин, В. В. Перепелица, Н. С. Буненков, Т. А. Лелявина

المصدر: Cancer Urology; Том 19, № 4 (2023); 148-157 ; Онкоурология; Том 19, № 4 (2023); 148-157 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: прогноз, biomarker, prostate biopsy, diagnostics, prognosis, биомаркеры, биопсия простаты, диагностика

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1686/1508; Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–49. DOI:10.3322/caac.21660; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.; Dudka I., Thysell E., Lundquist K. et al. Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status. BMC Cancer 2020;20(1):437. DOI:10.1186/s12885-020-06908-z; Рак предстательной железы. Клинические рекомендации. 2021. 124 с.; Lima A.R., Pinto J, Amaro F. et al. Advances and Perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics. Metabolites 2021;11(3):181. DOI:10.3390/metabo11030181; Магрупов Б.А., Иноятов У.Н. Морфологическая характеристика рака предстательной железы и его оценка по шкале Глисона. Вестник экстренной медицины 2020;13(4):50–7.; Lee S., Ku J.Y., Kang B.J. et al. Unique urinary metabolic feature for the determination of bladder cancer, prostate cancer, and renal cell carcinoma. Metabolites 2021;11(9):591. DOI:10.3390/metabo11090591; Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73(1):17–48. DOI:10.3322/caac.21763; Lahoud R.M., O’Shea A., El-Mouhayyar C. et al. Tumour markers and their utility in abdominal and pelvic malignancies. Clin Radiol 2021;76(2):99–107. DOI:10.1016/j.crad.2020.07.033; Абоян И.А., Федотова Е.Н., Шевченко А.Н. и др. Современные биомаркеры рака предстательной железы. Исследования и практика в медицине 2021;8(4):96–108. DOI:10.17709/2410-1893-2021-8-4-10; Li C.Y., Chen C.Y., An J.H. et al. Normal basal epithelial cells stimulate the migration and invasion of prostate cancer cell RM-1 by TGF-β1/STAT3 axis in vitro. Cancer Manag Res 2021;13:3685– 97. DOI:10.2147/CMAR.S303122; Agnello L., Vidali M., Giglio R.V. et al. Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2022;60(8):1261–77. DOI:10.1515/cclm-2022-0354; Othman H., Yamin A.H.A., Isa N.M. et al. Diagnostic performance of prostate health index (PHI) in predicting prostate cancer on prostate biopsy. Malays J Pathol 2020;42(2): 209–14.; Ferro M., Crocetto F., Bruzzese D. et al. Prostate health index and multiparametric MRI: partners in crime fighting overdiagnosis and overtreatment in prostate cancer. Cancers (Basel) 2021;13(18):4723. DOI:10.3390/cancers13184723; Stejskal J., Adamcová V., Záleský M. et al. The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy. World J Urol 2021;39(6):1889–95. DOI:10.1007/s00345-020-03397-4; Nassir A.M., Kamel H.F.M. Explication of the roles of prostate health index (PHI) and urokinase plasminogen activator (uPA) as diagnostic and predictor tools for prostate cancer in equivocal PSA range of 4–10 ng/mL. Saudi J Biol Sci 2020;27(8):1975–84. DOI:10.1016/j.sjbs.2020.04.004; Barisiene M., Bakavicius A., Stanciute D. et al. Prostate health index and prostate health index density as diagnostic tools for improved prostate cancer detection. Biomed Res Int 2020;2020: 9872146. DOI:10.1155/2020/9872146; Ito K., Yokomizo A., Tokunaga S. et al. Diagnostic impacts of clinical laboratory based p2PSA indexes on any grade, Gleason grade group 2 or greater, or 3 or greater prostate cancer and prostate specific antigen below 10 ng/mL. J Urol 2020;203(1):83–91. DOI:10.1097/JU.0000000000000495; Rasmussen M., Fredsøe J., Tin A.L. et al. Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence. Br J Cancer 2022;126(7):1004–9. DOI:10.1038/s41416-021-01661-x; Fredsøe J., Rasmussen M., Tin A.L. et al. Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine. Sci Rep 2022;12(1):15193. DOI:10.1038/s41598-022-19460-6; Mi C., Bai L., Yang Y. et al. 4Kscore diagnostic value in patients with high-grade prostate cancer using cutoff values of 7.5 % to 10 %: a meta-analysis. Urol Oncol 2021;39(6):366.e1–10. DOI:10.1016/j.urolonc.2020.11.001; Bhattu A.S., Zappala S.M., Parekh D.J., Punnen S. A 4Kscore cut-off of 7.5 % for prostate biopsy decisions provides high sensitivity and negative predictive value for significant prostate cancer. Urology 2021;148:53–8. DOI:10.1016/j.urology.2020.11.008; Falagario U.G., Martini A., Wajswol E. et al. Avoiding unnecessary Magnetic Resonance Imaging (MRI) and biopsies: negative and positive predictive value of MRI according to prostate-specific antigen density, 4Kscore and risk calculators. Eur Urol Oncol 2020;3(5):700–4. DOI:10.1016/j.euo.2019.08.015; Wysock J.S., Becher E., Persily J. et al. Concordance and performance of 4Kscore and SelectMDx for informing decision to perform prostate biopsy and detection of prostate cancer. Urology 2020;141:119–24. DOI:10.1016/j.urology.2020.02.032; Lonergan P.E., Vertosick E.A., Assel M. et al. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting highgrade prostate cancer in an international multicentre cohort. BJU Int 2021;128(2):218–24. DOI:10.1111/bju.15320; Sharma P.C., Gupta A. MicroRNAs: potential biomarkers for diagnosis and prognosis of different cancers. Transl Cancer Res 2020;9(9):5798–818. DOI:10.21037/tcr-20-1294; Mugoni V., Ciani Y., Nardella C., Demichelis F. Circulating RNAs in prostate cancer patients. Cancer Lett 2022;524:57–69. DOI:10.1016/j.canlet.2021.10.011; Долотказин Д.Р., Шкурников М.Ю., Алексеев Б.Я. Роль микроРНК в диагностике рака предстательной железы. Онкоурология 2020;16(4):172–80. DOI:10.17650/1726-9776-2020-16-4-172-180; Забегина Л.М., Никифорова Н.С., Назарова И.В. и др. Анализ микроРНК в ПСМА-положительной фракции внеклеточных нановезикул плазмы при раке предстательной железы. Онкоурология 2021;17(4):65–75. DOI:10.17650/1726-9776-2021-17-4-65-75; Kalogirou C., Linxweiler J., Schmucker P. et al. MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. Nat Commun 2021;12(1):5066. DOI:10.1038/s41467-021-25325-9; Bautista-Sánchez D., Arriaga-Canon C., Pedroza-Torres A. et al. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol Ther Nucleic Acids 2020;20: 409–20. DOI:10.1016/j.omtn.2020.03.003; Gandellini P., Ciniselli C.M., Rancati T. et al. Prediction of grade reclassification of prostate cancer patients on active surveillance through the combination of a three-miRNA signature and selected clinical variables. Cancers 2021;13(10):2433. DOI:10.3390/cancers13102433; Saltman A., Zegar J., Haj-Hamed M. et al. Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management? Ther Adv Urol 2021;13:1756287221997186. DOI:10.1177/1756287221997186; Gurung S., Perocheau D., Touramanidou L., Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal 2021;19(1):47. DOI:10.1186/s12964-021-00730-1; Yu W., Hurley J., Roberts D. et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol 2021;32(4):466–77. DOI:10.1016/j.annonc.2021.01.074; Tutrone R., Donovan M.J., Torkler P. et al. Clinical utility of the exosome based ExoDx Prostate (IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10ng/mL. Prostate Cancer Prostatic Dis 2020;23(4):607–14. DOI:10.1038/s41391-020-0237-z; McKiernan J., Noerholm M., Tadigotla V. et al. A urine-based exosomal gene expression test stratifies risk of high-grade prostate cancer in men with prior negative prostate biopsy undergoing repeat biopsy. BMC Urol 2020;20:138. DOI:10.1186/s12894-020-00712-4; Ramirez-Garrastacho M., Bajo-Santos C., Line A. et al. Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research. Br J Cancer 2022;126(3):331–50. DOI:10.1038/s41416-021-01610-8; Luca B.A., Moulton V., Ellis C. et al. Convergence of prognostic gene signatures suggests underlying mechanisms of human prostate cancer progression. Genes 2020;11:802. DOI:10.3390/genes11070802; Canter D.J., Freedland S., Rajamani S. et al. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. Prostate Cancer Prostatic Dis 2020;23:102–7. DOI:10.1038/s41391-019-0159-9; National Comprehensive Cancer Network. Prostate Cancer (Version 2.2021). (2021) [electronic resource]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (last accessed 18 April 2023).; Farha M.W., Salami S.S. Biomarkers for prostate cancer detection and risk stratification. Ther Adv Urol 2022;14:17562872221103988. DOI:10.1177/17562872221103988; Herlemann A., Huang H.C., Alam R. et al. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis 2020;23(1):136–43. DOI:10.1038/s41391-019-0167-9; Jairath N.K., Dal Pra A., Vince R.Jr. et al. A systematic review of the evidence for the decipher genomic classifier in prostate cancer. Eur Urol 2021;79(3):374–83. DOI:10.1016/j.eururo.2020.11.021; Feng F.Y., Sandler H.M., Huang H.C. et al. Transcriptome profiling of NRG oncology/RTOG 9601: validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial. J Clin Oncol 2020;38(6):276. DOI:10.1200/JCO.2020.38.6_suppl.276; Marascio J., Spratt D.E., Zhang J. et al. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer Prostatic Dis 2020;23(2):295–302. DOI:10.1038/s41391-019-0185-7; Koliadenko V., Wilanowski T. Additional functions of selected proteins involved in DNA repair. Free Radic Biol Med 2020;146:1–15. DOI:10.1016/j.freeradbiomed.2019.10.010; Uhr A., Glick L., Gomella L.G. An overview of biomarkers in the diagnosis and management of prostate cancer. Can J Urol 2020;27(S3):24–7.; Matuszczak M., Schalken J.A., Salagierski M. Prostate cancer liquid biopsy biomarkers’ clinical utility in diagnosis and prognosis. Cancers 2021;13:3373. DOI:10.3390/cancers13133373; Cullen J., Kuo H.C., Shan J. et al. The 17-Gene Genomic Prostate Score Test as a predictor of outcomes in men with unfavorable intermediate risk prostate cancer. Urology 2020;143:103–11. DOI:10.1016/j.urology.2020.05.045; Covas Moschovas M., Chew C., Bhat S. et al. Association between Oncotype DX Genomic Prostate Score and adverse tumor pathology after radical prostatectomy. Eur Urol Focus 2022;8(2):418–24. DOI:10.1016/j.euf.2021.03.015; Foley R.W., Redman S.L., Graham R.N. et al. Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positronemission tomography-computed tomography: normal patterns, pearls, and pitfalls. Clin Radiol 2020;75(12):903–13. DOI:10.1016/j.crad.2020.06.031; Maurer T., Gesterkamp H., Nguyen N. et al. 68Ga-PSMA-11 PET/ mpMRT zur Lokaldetektion des primären Prostatakarzinom bei Männern mit negativer Vorbiopsie [68Ga-PSMA-11 PET/mpMRI for local detection of primary prostate cancer in men with a negative prior biopsy (In German)]. Aktuelle Urol 2021;52(2):143–8. DOI:10.1055/a-1198-2305; Lopci E., Lughezzani G., Castello A. et al. PSMA-PET and microultrasound potential in the diagnostic pathway of prostate cancer. Clin Transl Oncol 2021;23(1):172–8. DOI:10.1007/s12094-020-02384-w; Plaza López P.J., Puertas E., Aguiló J.J. et al. 68Ga-PSMA-11 PET/CT in patients with occult biochemical recurrence of prostate carcinoma and negative 18F-Choline PET/CT. Preliminary assessment of its clinical use. Actas Urol Esp (Engl Ed) 202;45(5):353–8. DOI:10.1016/j.acuroe.2021.04.008; Progensa PCA3 Assay [electronic resource]. Available at: https:///www.hologic.com/sites/default/files/2019-05/502083-IFU-PI_003_01 (last accessed 17 April 2023).; Rodríguez S.V.M., García-Perdomo H.A. Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: a systematic review and meta-analysis. Can Urol Assoc J 2020;14(5):E214–9. DOI:10.5489/cuaj.6008; Lee D., Shim S.R., Ahn S.T. et al. Diagnostic performance of the prostate cancer antigen 3 test in prostate cancer: systematic review and meta-analysis. Clin Genitourin Cancer 2020;18(5):402–8.e5. DOI:10.1016/j.clgc.2020.03.005; Jiao B., Gulati R., Hendrix N. et al. Economic evaluation of urinebased or magnetic resonance imaging reflex tests in men with intermediate prostate-specific antigen levels in the United States. Value Health 2021;24(8):1111–7. DOI:10.1016/j.jval.2021.02.009; Tosoian J.J., Trock B.J., Morgan T.M. et al. Use of the MyProstateScore Test to rule out clinically significant cancer: validation of a straightforward clinical testing approach. J Urol 2021;205(3):732–9. DOI:10.1097/JU.0000000000001430; Tosoian J.J., Singhal U., Davenport M.S. et al. Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need. Urology 2022;164:184–90. DOI:10.1016/j.urology.2021.11.033; Sessine M., Morgan T., Wei J. et al. Use of the MyProstateScore test for risk stratification in men with a previous negative biopsy: initial validation of a straightforward testing approach. J Urol 2021;206(Suppl 3):e467. DOI:10.1097/JU.0000000000002023.12; Schmidt D.R., Patel R., Kirsch D.G. et al. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J Clin 2021;71(4):333–58. DOI:10.3322/caac.21670; Berenguer C.V., Pereira F., Pereira J.A.M., Câmara J.S. Volatilomics: an emerging and promising avenue for the detection of potential prostate cancer biomarkers. Cancers (Basel) 2022;14(16):3982. DOI:10.3390/cancers14163982; Lima A.R., Pinto J., Barros-Silva D. et al. New findings on urinary prostate cancer metabolome through combined GC–MS and 1H NMR analytical platforms. Metabolomics 2020;16:1–9. DOI:10.1007/s11306-020-01691-1; Salciccia S., Capriotti A.L., Lagana A. et al. Biomarkers in prostate cancer diagnosis: from current knowledge to the role of metabolomics and exosomes. Int J.Mol Sci 2021;22:4367. DOI:10.3390/ijms22094367; Filianoti A., Costantini M., Bove A.M. et al. Volatilome analysis in prostate cancer by electronic nose: a pilot monocentric study. Cancers 2022;14:2927. DOI:10.3390/cancers14122927.54; Taverna G., Grizzi F., Tidu L. et al. Accuracy of a new electronic nose for prostate cancer diagnosis in urine samples. Int J Urol 2022;29:890–6. DOI:10.1111/iju.14912; Capelli L., Bax C., Grizzi F., Taverna G. Optimization of training and measurement protocol for eNose analysis of urine headspace aimed at prostate cancer diagnosis. Sci Rep 2021;11:20898. DOI:10.1038/s41598-021-00033-y; Waltman C.G., Marcelissen T.A.T., van Roermund J.G.H. Exhaled-breath testing for prostate cancer based on volatile organic compound profiling using an Electronic Nose Device (Aeonose™): a preliminary report. Eur Urol Focus 2020;6:1220–5. DOI:10.1016/j.euf.2018.11.006; https://oncourology.abvpress.ru/oncur/article/view/1686

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1686
https://doi.org/10.17650/1726-9776-2023-19-4-148-157

المؤلفون: S. V. Popov, R. G. Huseynov, I. A. Miloserdov, Yu. V. Kisil, D. A. Saydulaev, S. V. Sadovnikov, K. V. Sivak, N. S. Bunenkov, V. V. Perepelitsa, T. A. Lelyavina, С. В. Попов, Р. Г. Гусейнов, И. А. Милосердов, Ю В. Кисиль, Д. А. Сайдулаев, С. В. Садовников, К. В. Сивак, Н. С. Буненков, В. В. Перепелица, Т. А. Лелявина

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 25, № 3 (2023); 57-63 ; Вестник трансплантологии и искусственных органов; Том 25, № 3 (2023); 57-63 ; 2412-6160 ; 1995-1191

مصطلحات موضوعية: перкутанная нефролитотрипсия, nephrolithiasis, extracorporeal shock wave lithotripsy, ureteroscopy, percutaneous nephrolithotripsy, нефролитиаз, дистанционная ударно-волновая литотрипсия, уретероскопия

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/1620/1508; Palazzo S, Colamonico O, Forte S, Matera M, Lucarelli G, Ditonno P et al. Experience of percutaneous access under ultrasound guidance in renal transplant patients with allograft lithiasis. Arch Ital Urol Androl. 2016; 88 (4): 337–340. doi:10.4081/aiua.2016.4.337.; Markić D, Krpina K, Ahel J, Gršković A, Španjol J, Rubinić N et al. Treatment of Kidney Stone in a KidneyTransplanted Patient with Mini-Percutaneous Laser Lithotripsy: A Case Report. Case Rep Nephrol Dial. 2016; 6 (1): 26–31. doi:10.1159/000444251.; Лопаткин НА, Трапезникова МФ, Перлин ДВ. Урологические осложнения при трансплантации почки. М., 2004: 174–190.; Li SD, Wang QT, Chen WG. Treatment of urinary lithiasis following kidney transplantation with extracorporeal shock-wave lithotripsy. Chinese Medical Journal. 2011; 124 (9): 1431–1434.; Abbott KC, Schenkman N, Swanson SJ, Agodoa LY. Hospitalized nephrolithiasis after renal transplantation in the United States. Am J Transplant. 2003; 3 (4): 465–470. doi:10.1034/j.1600-6143.2003.00080.x.; Cheungpasitporn W, Thongprayoon C, Mao MA, Kittanamongkolchai W, Jaffer Sathick IJ, Dhondup T, Erickson SB. Incidence of kidney stones in kidney transplant recipients: a systematic review and meta-analysis. World J Transplant. 2016; 6 (4): 790–797. doi:10.5500/wjt.v6.i4.790.; Santillán D, Scherñuk Schroh JC, Gutierrez PA, Thomas F, Tirapegui FI, Moldes J et al. Case Report: Miniendoscopic combined intrarenal surgery in an en-bloc kidney transplant. Afr J Urol. 2021; 27 (1): 147. doi:10.1186/s12301-021-00249-4.; Kim H, Cheigh JS, Ham HW. Urinary stones following renal transplantation. Korean J Intern Med. 2001; 16 (2): 118–122. doi:10.3904/kjim.2001.16.2.118.; Bolen E, Stern K, Humphreys M, Brady A, Leavitt T, Zhang N, Keddis M. Urine metabolic risk factors and outcomes of patients with kidney transplant nephrolithiasis. Clinical Kidney Journal. 2021; 15 (3): 500–506. doi:10.1093/ckj/sfab208.; Li X, Li B, Meng Y, Yang L, Wu G, Jing H et al. Treatment of recurrent renal transplant lithiasis: analysis of our experience and review of the relevant literature. BMC Nephrol. 2020; 21 (1): 238. doi:10.1186/s12882-020- 01896-5.; Branchereau J, Timsit MO, Neuzillet Y, Bessède T, Thuret R, Gigante M et al. Management of renal transplant urolithiasis: A multicentre study by the French Urology Association Transplantation Committee. World J Urol. 2018; 36 (1): 105–109. doi:10.1007/s00345-017-2103-8.; Mohammadi A, Nikoobakht MR, Hosseini SR. Urolithiasis in Renal Transplantation Patients: An Update of the Literature. Translational Research in Urology. 2021; 3 (4): 149–153. doi:10.22034/TRU.2021.305308.1081.; Geraghty R, Wood K, Sayer JA. Calcium oxalate crystal deposition in the kidney: identification, causes and consequences. Urolithiasis. 2020; 48 (5): 377–384. doi:10.1007/s00240-020-01202-w.; Eslahi A, Salehipour M, Hosseini MM, Ahmed F, Hosseini SH, Ghafari S. Mini-percutaneous nephrolithotomy via ultrasound guidance in transplanted kidney: a report of two cases. Pan Afr Med J. 2022; 41: 333. doi:10.11604/pamj.2022.41.333.33169.; He Z, Li X, Chen L, Zeng G, Yuan J. Minimally invasive percutaneous nephrolithotomy for upper urinary tract calculi in transplanted kidneys. BJU Int. 2007; 99 (6): 1467–1471. doi:10.1111/j.1464-410X.2007.06768.x.; Kadlec AO, Ross MJ, Milner JE. Mini-percutaneous nephrolithotomy with ureteral access sheath in a transplanted kidney: case report and literature review. Urol Int. 2013; 91 (2): 236–238. doi:10.1159/000343987.; Garg M, Johnson H, Lee SM, Rai BP, Somani B, Philip J. Role of Hounsfield Unit in Predicting Outcomes of Shock Wave Lithotripsy for Renal Calculi: Outcomes of a Systematic Review. Current Urology Reports. 2023; 24 (4): 173–185. doi:10.1007/s11934-023-01145-w.; Serrell EC, Best SL. Imaging in stone diagnosis and surgical planning. Current Opinion in Urology. 2022; 32 (4): 397–404. doi:10.1097/MOU.0000000000001002.; Elbaset MA, Taha DE, Anas M, Abouelkheir RT, Edwan M, Abdullateef M et al. Optimization of shockwave lithotripsy use for single medium sized hard renal stone with stone density ≥1000 HU. A prospective study. World J Urol. 2022; 40 (1): 243–250. doi:10.1007/s00345-021-03807-1.; Лубенников АЕ, Трушкин РН, Артюхина ЛЮ. Нефролитиаз у реципиентов почечного трансплантата. Клиническая нефрология. 2016; (3–4): 69–74.; Millán Rodríguez F, González de Chaves E, Rousaud Barón F, Izquierdo Latorre F, Rousaud Barón A. Treatment of urinary calculi in transplanted kidney with extracorporeal shock wave lithotripsy. Arch Esp Urol. 2003; 56 (7): 793–798.; Klingler HC, Kramer G, Lodde M, Marberger M. Urolithiasis in allograft kidneys. Urology. 2002; 59 (3): 344– 348. doi:10.1016/s0090-4295(01)01575-8.; Challacombe B, Dasgupta P, Tiptaft R, Glass J, Koffman G, Goldsmith D,Khan MS. Multimodal management of urolithiasis in renal transplantation. BJU Int. 2005; 96 (3): 385–389. doi:10.1111/j.1464-410X.2005.05636.x.; Yuan HJ, Yang DD, Cui YS, Men CP, Gao ZL, Shi L, Wu JT. Minimally invasive treatment of renal transplant nephrolithiasis. World J Urol. 2015; 33 (12): 2079–2085. doi:10.1007/s00345-015-1549-9.; Li X, He Z, Wu K, Li SK, Zeng G, Yuan J et al. Chinese minimally invasive percutaneous nephrolithotomy: the Guangzhou experience. J Endourol. 2009; 23 (10): 1693–1697. doi:10.1089/end.2009.1537.; Ji ZG, Tian Y, Chen YQ, Liu Z, Lin J, Wang JM et al. A Retrospective Study of minipercutaneous laser lithotripsy for treatment of allograft kidney Lithiasis Obstruction. Transpl Proc. 2013; 45 (9): 3298–3301. doi:10.1016/j.transproceed.2013.06.007.; Basiri A, Nikoobakht MR, Simforoosh N, Hosseini Moghaddam SM. Ureteroscopic management of urological complications after renal transplantation. Scand J Urol Nephrol. 2006; 40 (1): 53–56. doi:10.1080/00365590510007838.; Hyams E, Marien T, Bruhn A, Quirouet A, Andonian S, Shah O, Matlaga B. Ureteroscopy for transplant lithiasis. J Endourol. 2012; 26 (7): 819–822. doi:10.1089/end.2011.0495.; Sarier M, Duman I, Yuksel Y, Tekin S, Demir M, Arslan F et al. Results of minimally invasive surgical treatment of allograft lithiasis in liver donor renal transplant recipients: A single center experience of 3758 renal transplantations. Urolithiasis. 2019; 47 (3): 273–278. doi:10.1007/s00240-018-1051-0.; Gerber RC, Best SL, Hedican SP, Nakada SY. Flexible Ureteroscopy as the New Standard for the Management of Renal Transplant Urolithiasis; https://journal.transpl.ru/vtio/article/view/1620

الاتاحة: https://journal.transpl.ru/vtio/article/view/1620
https://doi.org/10.15825/1995-1191-2023-3-57-63

المؤلفون: S. V. Popov, R. G. Huseynov, D. A. Saydulaev, S. V. Sadovnikov, Yu. V. Kisil, K. V. Sivak, N. S. Bunenkov, V. V. Perepelitsa, A. S. Ulitina, T. A. Lelyavina, С. В. Попов, Р. Г. Гусейнов, Д. А. Сайдулаев, С. В. Садовников, Ю. В. Кисиль, К. В. Сивак, Н. С. Буненков, В. В. Перепелица, А. С. Улитина, Т. А. Лелявина

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 25, № 2 (2023); 15-25 ; Вестник трансплантологии и искусственных органов; Том 25, № 2 (2023); 15-25 ; 2412-6160 ; 1995-1191

مصطلحات موضوعية: трансплантация почки, benign prostatic hyperplasia, kidney transplantation, доброкачественная гиперплазия предстательной железы

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/1603/1467; https://journal.transpl.ru/vtio/article/downloadSuppFile/1603/1265; Годовой отчет о трансплантологии в Европе за 2019 год. https://www.eurotransplant.org/wp-content/uploads/2020/06/AnnualReport-2019.pdf.; Готье СВ, Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2018 году. XII сообщение Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2019; 21 (3): 7–32. https://doi.org/10.15825/1995-1191-2019.; Кабанова СА, Богопольский ПМ. Пересадка почки: история, итоги и перспективы. Трансплантология. 2015; (2): 49–58.; Султанов ПК, Хаджибаев ФА, Эргашев ДН, Исматов АА. Анализ осложнений после трансплантации почки. Вестник экстренной медицины. 2021; 14 (1): 55–63.; Dos Santos Mantovani M, Coelho de Carvalho N, Archangelo TE, Modelli de Andrade LG, Pires Ferreira Filho S, de Souza Cavalcante R et al. Frailty predicts surgical complications after kidney transplantation. A propensity score matched study. PLoS One. 2020 Feb 26; 15 (2): e0229531.; Bessede T, Hammoudi Y, Bedretdinova D, Parier B, Francois H, Durrbach A, Benoit G. Preoperative Risk Factors Associated With Urinary Complications After Kidney Transplantation. Transplant Proc. 2017 Nov; 49 (9): 2018–2024.; Hickman LA, Sawinski D, Guzzo T, Locke JE. Urologic malignancies in kidney transplantation. Am J Transplant. 2018 Jan; 18 (1): 13–22.; Shimizu T, Sugihara T, Kamei J, Takeshima S, Kinoshita Y, Kubo T et al. Predictive factors and management of urinary tract infections after kidney transplantation: a retrospective cohort study. Clin Exp Nephrol. 2021 Feb; 25 (2): 200–206.; Thuret R, Timsit MO, Kleinclauss F. Chronic kidney disease and kidney transplantation. Prog Urol. 2016 Nov; 26 (15): 882–908.; Billis A, Freitas LLL, Costa LBE, Barreto IS, Botega AAR, Pereira TA, D’Ancona CA. Lower Urinary Tract Symptoms Due to Xanthoma of the Prostate After Kidney Transplantation: A Case Report. Transplant Proc. 2020 Nov; 52 (9): 2736–2738.; Frascà GM, Brigante F, Volpe A, Cosmai L, Gallieni M, Porta C. Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. J Nephrol. 2019 Feb; 32 (1): 57–64.; Tan JHS, Bhatia K, Sharma V, Swamy M, van Dellen D, Dhanda R, Khambalia H. Enhanced recovery after surgery recommendations for renal transplantation: guidelines. Br J Surg. 2022 Dec 13; 110 (1): 57–59.; Thuret R, Kleinclauss F, Terrier N, Karam G, Timsit MO. Challenges in renal transplantation. Prog Urol. 2016 Nov; 26 (15): 1001–1044. 14. Maggiore U, Abramowicz D, Budde K. Renal transplantation in the elderly. Transplant Rev (Orlando). 2015 Oct; 29 (4): 191–192.; Rodríguez Faba O, Boissier R, Budde K, Figueiredo A, Taylor CF, Hevia V et al. European Association of Urology Guidelines on Renal Transplantation: Update 2018. Eur Urol Focus. 2018 Mar; 4 (2): 208–215.; Cheung CY, Tang SCW. An update on cancer after kidney transplantation. Nephrol Dial Transplant. 2019 Jun 1; 34 (6): 914–920.; Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tractsymptoms: prevalence and incident rates. Urol Clin North Am. 2016; 43: 289.; De Oliveira Marinho AC, Tavares­da­Silva E, Bastos CA, Roseiro A, Parada B, Retroz E et al. Acute Urinary Retention After Kidney Transplant: Effect on Graft Function, Predictive Factors, and Treatment. Transplant Proc. 2021 Jul-Aug; 53 (6): 1933–1938.; Sarier M, Yayar O, Yavuz A, Turgut H, Kukul E. Update on the Management of Urological Problems Following Kidney Transplantation. Urol Int. 2021; 105 (7–8): 541–547.; Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I – Initial Work-up and Medical Management. J Urol. 2021 Oct; 206 (4): 806–817.; Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II – Surgical Evaluation and Treatment. J Urol. 2021 Oct; 206 (4): 818–826.; Касян ГР, Ходырева ЛА, Дударева АА и др. Комбинированное лечение симптомов нижних мочевых путей у мужчин. Медицинский совет. 2016; 5: 84–90.; Seo JH, Han JS, Lee Y, Myong JP, Ha US. Fall risk related to subtype-specific alpha-antagonists for benign prostatic hyperplasia: a nationwide Korean populationbased cohort study. World J Urol. 2022 Dec; 40 (12): 3043–3048.; Пушкарь ДЮ, Раснер ПИ, Харчилава РР. Российские клинические рекомендации с современными данными ведущих российских специалистов. Симптомы нижних мочевыводящих путей и доброкачественная гиперплазия предстательной железы. Урология. 2016; (2, прилож.): 4–19.; Раснер ПИ, Газимиев МА, Гаджиева ЗК и др. Расстройства мочеиспускания у мужчин: методические рекомендации, № 6. М.: АБВ-пресс, 2017; 35.; Павлов ВН, Галимзянов ВЗ, Казихинуров АА, Пушкарев АМ, Загитов АР, Казихинурова АА, Шарипов ИР. Симптомы нижних мочевыводящих путей и доброкачественная гиперплазия предстательной железы: учебное пособие. Уфа: БГМУ, 2018; 86.; Foster HE, Dahm P, Kohler TS et al. Surgical management of lower urinary tract symptom sattributed to benign prostatic hyperplasia: AUA Guideline amendment 2019. J Urol. 2019; 202: 592.; Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2013; 189 (1 Suppl): S122–S128.; Homma Y, Kawabe K, Tsukamoto T et al. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int J Urol. 1996; 3: 261–266.; Debruyne F, Boyle P, Calais Da Silva F et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients – PERMAL study subset analysis. Eur Urol. 2004; 45: 773–779.; Razek M, Abolyosr A, Mhammed O, Fathi A, Talaat M, Hassan A. Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World J Urol. 2022. Aug; 40 (8): 2063–2070.; Lukacs B, Grange JC, Comet D. One-year follow-up of 2829 patients with moderate to severe lower urinarytract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice Urology. 2000; 55: 540–546.; Barendrecht MM, Abrams P, Schumacher H, de a Rosette JJ, Michel MC. Do α1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn. 2008; 27: 226–230.; Fusco F, Creta M, De Nunzio C et al. Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urol. 2018; 18: 15.; Gul ZG, Kaplan SA. BPH: why do patients fail medical therapy? Curr Urol Rep. 2019; 20: 40.; La Vignera S, Aversa A, Cannarella R, Condorelli RA, Duca Y, Russo GI, Calogero AE. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother. 2021 Feb; 22 (2): 179–189.; Alcaraz A, Castro­Díaz D, Gacci M, Salonia A, Ficarra V, Carballido­Rodríguez J et al. Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-toSevere LUTS-BPH Patients: Results of a Paired Matched Clinical Study. On Behalf Of The Qualiprost Study Group. J Clin Med. 2022 Jun 22; 11 (13): 3615.; Bauer SR, Walter LC, Ensrud KE, Suskind AM, Newman JC, Ricke WA et al. Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. JAMA Netw Open. 2021 Nov 1; 4 (11): e2134427.; Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. Comparative analysis of the effectiveness of early and delayed initiation of combined DRUG therapy for bph. Urologiia. 2021 May; (2): 27–30.; Gravas S, Cornu JN, Gacci M et al. EAU guidelines on management of non-neurogenic male LUTS. Presented at 2020 EAU Annual Congress, Amsterdam, Arnhem, The Netherlands. Available at http://uroweb.org/guidelines/compilations-of-all-guidelines/.; Anderson BB, Pariser JJ, Helfand BT. Comparison of Patients Undergoing PVP Versus TURP for LUTS/BPH. Curr Urol Rep. 2015 Aug; 16 (8): 55.; Drouin S, Defortescu G, Prudhomme T, Culty T, Verhoest G, Doerfler A et al. Lower urinary tract symptoms and urinary incontinence in renal transplant recipients and candidates: The French guidelines from CTAFU. Prog Urol. 2021 Jan; 31 (1): 45–49.; Checcucci E, Veccia A, De Cillis S, Piramide F, Volpi G, Amparore D et al. New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes. Uro-technology and SoMe Working Group of the Young Academic Urologists Working Party of the European Association of Urology and of the Lower Tract and Research Group of the European Section of Uro-technology. Eur Urol Open Sci. 2021 Sep 22; 33: 28–41.; Righetto M, Mancini M, Modonutti D, Calpista A, Beltrami P, Dal Moro F. Patients with renal transplant and moderate-to-severe LUTS benefit from urodynamic evaluation and early transurethral resection of the prostate. World J Urol. 2021 Dec; 39 (12): 4397–4404.; Sarier M, Tekin S, Duman İ, Yuksel Y, Demir M, Alptekinkaya F et al. Results of transurethral resection of the prostate in renal transplant recipients: a single center experience. World J Urol. 2018 Jan; 36 (1): 99–103.; Rassweiler J, Teber D, Kuntz R et al. Complications of transurethral resection of the prostate (TURP) dincidence, management, and prevention. Eur Urol. 2006; 50: 969.; Liu Z, Li YW, Wu WR et al. Long-term clinicale fficacy and safety profile of transurethral resection of prostate versus plasma kinetic resection of the prostate for benign prostatic hyperplasia. Urology. 2017; 103: 198.; Friedl A, Schneeweiss J, Stangl K et al. The adjustable transobturator male system in stress urinary incontinence after transurethral resection of the prostate. Urology. 2017; 109: 184.; Boston Scientific Corporation: Intended use. Rezum Instruction for Use, 10-2019; 5.; Dixon CM, Rijo Cedano E, Mynderse LA et al. Transurethral convective water vapor as atreatment for lower urinary tract symptom-atology due to benign prostatic hyperplasiausing the Rezum(R) system: evaluation of acuteablative capabilities in the human prostate. Res Rep Urol. 2015; 7: 13.; Bouza C, Lopez T, Magro A et al. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol. 2006; 6: 14.; McVary KT, Rogers T, Mahon J et al. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J Sex Med. 2018; 15: 1728.; National Institute for Health and Care Excellence: Rezum for treating lower urinary tractsymptoms secondary to benign prostatic hyperplasia (24 June 2020). NICE Guideline No. MTG49.; Mynderse LA, Roehrborn CG, Partin AW et al. Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. J Urol. 2011; 185: 1804.; Gravas S, Cornu JN, Gacci M et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Arnhem, The Netherlands: EAU Guidelines Office. 2020.; McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal therapy for lower urinarytract symptoms associated with benign prostatichyperplasia: 4-year results from randomized controlled study. Urology. 2019; 126: 171.; McVary KT, Roehrborn CG. Three-year out-comes of the prospective, randomized controlled Rezum System Study: convective radio frequency thermal therapy for treatment of lower urinarytract symptoms due to benign prostatic hyperplasia. Urology. 2018; 111: 1.; U.S. Food and Drug Administration: Select Up-dates for Guidance for the Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH): Draft Guidance for Industry and Food and Drug Administration Staff (July 14, 2020).; Roehrborn CG, Wilson TH, Black LK. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. J Urol. 2012; 187: 1732.; Miller LE, Chughtai B, Dornbier RA et al. Surgical reintervention rate after prostatic urethral lift: systematic review and meta-analysis involving over 2,000 patients. J Urol. 2020; 204: 1019.; Roehrborn CG, Barkin J, Gange SN et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017; 24: 8802.; Zlotta AR, Giannakopoulos X, Maehlum O et al. Longterm evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol. 2003; 44: 89.; Rosario DJ, Phillips JT, Chapple CR. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails. J Urol. 2007; 177: 1047.; Hill B, Belville W, Bruskewitz R et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol. 2004; 171: 2336.; Gupta N, Rogers T, Holland B et al. Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol. 200; 405: 2018.; Malde S, Rajagopalan A, Patel N et al. Potassium-titanyl-phosphate laser photoselective vaporization for benign prostatic hyperplasia: 5-year follow-up from a district general hospital. J Endourol. 2012; 26: 878.; Lee HE, Kim B, Yoon HS, Suh J, Oh SJ. Outcome of Patients With Elevated Prostate-Specific Antigen and Lower Urinary Tract Symptoms Receiving Holmium Laser Enucleation of the Prostate. Int Neurourol J. 2022 Sep; 26 (3): 248–257.; Takeuchi Y, Sawada Y, Watanabe S, Ni­Itsu Y, Sekido N. Age-specific effect of transurethral holmium laser enucleation of the prostate on overactive bladder in men with benign prostatic hyperplasia: An investigation using an overactive bladder symptom score. Low Urin Tract Symptoms. 2022 Dec 11.; Nohara T, Matsuyama S, Shima T, Kawaguchi S, Seto C. Holmium Laser Enucleation of the Prostate With Percutaneous Nephrostomy Into the Transplanted Kidney in Patient With Severe Benign Prostatic Hyperplasia With Vesicoureteral Reflux – A Case Report. Urol Case Rep. 2015 Dec 10; 4: 33–35.; Prudhomme T, Marquette T, Péré M. Benign Prostatic Hyperplasia Endoscopic Surgical Procedures in Kidney Transplant Recipients: A Comparison Between Holmium Laser Enucleation of the Prostate, GreenLight Photoselective Vaporization of the Prostate, and Transurethral Resection of the Prostate. J Endourol. 2020 Feb; 34 (2): 184–191.; Baboudjian M, Fourmarier M, Gondran­Tellier B, Pradere B, Userovici M, Alegorides C, Barry Delongchamps N. Head-to-head comparison of prostatic urethral lift and water vapor thermal therapy for the treatment of symptomatic benign prostatic hyperplasia: a real-life study. Int Urol Nephrol. 2021 Sep; 53 (9): 1757–1763.; Alexander CE, Scullion MM, Omar MI, Yuan Y, Mamoulakis C, N’Dow JM et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2019 Dec 3; 12 (12): CD009629.; Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus monopolar transurethral resection of the prostate: A systematic review and meta-analysis of randomized controlled trials. Eur Urol. 2009; 56: 798–809. doi:10.1016/j.eururo.2009.06.037.; Ahyai SA, Gilling P, Kaplan SA et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010; 58: 384–397.; Burke N, Whelan JP, Goeree L et al. Systematic review and meta-analysis of transurethral resection of the prostate vs. minimally invasive procedures for the treatment of benign prostatic obstruction. Urology. 2010; 75: 1015–1022.; Omar MI, Lam TBL, Cameron A et al. Systematic review and meta-analysis of the clinical effectiveness of bipolar compared to monopolar transurethral resection of the prostate. BJU Int. 2014; 113: 24–35.; Cornu JN, Ahyai S, Bachmann A et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: An update. Eur Urol. 2015; 67: 1066–1096.; Mamoulakis C, Sofras F, de la Rosette J et al. Bipolar vs. monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2014; 1: CD009629.; Taylor BL, Jaffe WI. Electrosurgical transurethral resection of the prostate and transurethral incision of the prostate (monopolar techniques). Can J Urol. 2015 Oct; 22 Suppl 1: 24–29.; Sarıer M, Duman İ, Demir M, Yüksel Y, Emek M, Kukul E. The outcomes of transurethral incision/resection of the prostate (TUIP/TURP) performed early afterrenal transplantation. Turk J Urol. 2018 Mar; 44 (2): 172–177.; Sarier M, Duman I, Kilic S, Yuksel Y, Demir M, Aslan M et al. Comparative Results of Transurethral Incision with Transurethral Resection of The Prostate in Renal Transplant Recipients with Benign Prostate Hyperplasia. Urol J. 2018 Jul 10; 15 (4): 209–213.; Duty BD, Conlin MJ, Fuchs EF, Barry JM. The current role of endourologic management of renal transplantation complications. Adv Urol. 2013; 2013: 246520.; Cardi A, Palleschi G, Patruno G, Tuffu G, D’Amico FE, De Vico A et al. Robot-assisted simple prostatectomy for treatment of large prostatic adenomas: surgical technique and outcomes from a high-volume robotic centre. World J Urol. 2022 Dec 25.; Law YXT, Chen WJK, Shen L, Chua WJ. Is transurethral needle ablation of prostate out of fashion? Outcomes of single session office-based transurethral needle ablation of prostate in patients with symptomatic benign prostatic hyperplasia. Investig Clin Urol. 2019 Sep; 60 (5): 351–358.; Powell T, Rahman S, Staib L, Bhatia S, Ayyagari R. Operator Learning Curve for Prostatic Artery Embolization and Its Impact on Outcomes in 296 Patients. Cardiovasc Intervent Radiol. 2022 Dec 1.; Goyal P, Salem R, Mouli SK. Controversies in Prostate Artery Embolization: Future Best Practice. Semin Intervent Radiol. 2022 Dec 20; 39 (6): 562–570.; Gondran­Tellier B, McManus R, Sichez PC, Akiki A, Gaillet S, Toledano H et al. Efficacy and Safety of Surgery for Benign Prostatic Obstruction in Patients with Preoperative Urinary Catheter. J Endourol. 2021 Jan; 35 (1): 102–108.; Яремин БИ, Харитонов БИ, Миронов АА, Масликова УВ, Александрова ВЭ. Трансплантация почки – поиск оптимальной хирургической техники. Вестник медицинского института «РЕАВИЗ». 2017; (5): 94–104.; Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020 Apr; 104 (4S1 Suppl 1): S11–S103.; Choudhury S, Haldar B, Pal DK. Spectrum of lower urinary tract symptoms after renal transplant among adult non-urologic anuric patients and their management in a tertiary care center. Urologia. 2022 Feb 3: 3915603211048150. doi:10.1177/03915603211048150.; Клинические рекомендации Европейской ассоциации урологов [Электронный ресурс]. М.: Медконгресс, 2019; 1368.; Интегративная урология. Руководство для врачей / Под ред. П.В. Глыбочко, Ю.Г. Аляева. М.: Медфорум, 2014: 128–239, 314–326.; na P, Baboudjian M, Piana A, Girón I et al. New Generation Pulse Modulation in Holmium:YAG Lasers: A Systematic Review of the Literature and Meta-Analysis. J Clin Med. 2022 Jun 4; 11 (11): 3208.; Perri A, Izzo G, Lofaro D, La Vignera S, Brunetti A, Calogero AE, Aversa A. Erectile Dysfunction after Kidney Transplantation. J Clin Med. 2020 Jun 25; 9 (6): 1991.; Kleinclauss F, Thuret R, Murez T, Timsit MO. Urologic malignancies in renal transplant candidates and recipients. Prog Urol. 2016 Nov; 26 (15): 1094–1113.; Данович МГ. Трансплантация почки. Пер. с англ. под ред. Я.Г. Мойсюка. М.: ГЭОТАР Медиа, 2014; 848.; Latchamsetty KC, Mital D, Jensik S. Use of collagen injections for vesicoureteral reflux in transplanted kidney. Transplant Proc. 2003; 35: 1378.; Li Marzi V, Filocamo MT, Dattolo E. The treatment of fistulae and ureteral stenosis after kidney transplantation. Transplant Proc. 2005; 37: 2516.; Mokos I, Kastelan Z, Basić­Jukić N, Kes P, Pasini J. Transurethral incision/resection of the prostate (TUIP/ TURP) in operative treatment of repeated bladder outlet obstruction early after kidney transplantation. Acta Clin Croat. 2011 Sep; 50 (3): 381–384.; Védrine N, Nsabimbona B, Soares P, Deteix P, Boiteux JP, Guy L. Transurethral resection or incision of the prostate in the immediate postoperative follow-up of renal transplantation. Prog Urol. 2009 Dec; 19 (11): 845–849.; Gratzke C, Pahde A, Dickmann M, Reich O, Seitz M, Jauch K et al. Predictive factors for urinary retention following kidney transplantation in male patients. Scand J Urol Nephrol. 2012 Feb; 46 (1): 44–47.; Gill BC, Ulchaker JC. Costs of managing benign prostatic hyperplasia in the office and operating room. Curr Urol Rep. 2018; 19: 72.; https://journal.transpl.ru/vtio/article/view/1603

الاتاحة: https://journal.transpl.ru/vtio/article/view/1603
https://doi.org/10.15825/1995-1191-2023-2-15-25

المؤلفون: S. V. Popov, R. G. Guseynov, Ye. V. Pomeshkin, K. V. Sivak, V. V. Perepelitsa, K. A. Nadein, N. S. Bunenkov, A. S. Ulitina, С. В. Попов, Р. Г. Гусейнов, Е. В. Помешкин, К. В. Сивак, В. В. Перепелица, К. А. Надеин, Н. С. Буненков, А. С. Улитина

المصدر: Research and Practical Medicine Journal; Том 10, № 2 (2023); 104-117 ; Research'n Practical Medicine Journal; Том 10, № 2 (2023); 104-117 ; 2410-1893 ; 10.17709/2410-1893-2023-10-2

مصطلحات موضوعية: биомаркеры, chronic kidney disease, acute kidney injury, ferroptosis, hyperkalemia, biomarkers, хроническая болезнь почек, острое почечное повреждение, ферроптоз, гиперкалиемия

وصف الملف: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/888/556; https://www.rpmj.ru/rpmj/article/view/888/568; https://www.rpmj.ru/rpmj/article/downloadSuppFile/888/751; https://www.rpmj.ru/rpmj/article/downloadSuppFile/888/752; Du Z, Chen W, Xia Q, Shi O, Chen Q. Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study. Biomark Res. 2020 May 13;8:16. https://doi.org/10.1186/s40364-020-00195-3; Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Pract. 2013;2013:479730. https://doi.org/10.1155/2013/479730; Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79–87. https://doi.org/10.14740/wjon1279; Farooqi S, Dickhout JG. Major comorbid disease processes associated with increased incidence of acute kidney injury. World J Nephrol. 2016 Mar 6;5(2):139–146. https://doi.org/10.5527/wjn.v5.i2.139; Rosner MH, Perazella MA. Acute kidney injury in the patient with cancer. Kidney Res Clin Pract. 2019 Sep 30;38(3):295–308. https://doi.org/10.23876/j.krcp.19.042; Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers. 2021;7(1):52. https://doi.org/10.1038/s41572-021-00284-z; Sundström J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al.; CaReMe CKD Investigators. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. Lancet Reg Health Eur. 2022 Jun 30;20:100438. https://doi.org/10.1016/j.lanepe.2022.100438; Кульченко Н. Г. Лечение локализованного рака почки. Южно-Российский онкологический журнал. 2020;1(1):69–75. https://doi.org/10.37748/2687-0533-2020-1-1-6; Шевченко А. Н., Бреус А. А., Нескубина И. В., Дженкова Е. А., Филатова Е. В., Швырёв Д. А. Оценка прогностической значимости некоторых биологических факторов при локальном и генерализованном светлоклеточном раке почки. Южно-Российский онкологический журнал. 2020;1(1):6–22. https://doi.org/10.37748/2687-0533-2020-1-1-1; Димитриади С. Н., Ушакова Н. Д., Величко А. В., Франциянц Е. М. Оценка корригирующего влияния лечебного плазмафереза на состояние почечной функции у больных после хирургического лечения локализованного рака почки. Южно-Российский онкологический журнал. 2021;2(2):6–14. https://doi.org/10.37748/2686-9039-2021-2-2-1; Sokolov DV, Polushin YS. Acute renal injury in the peri-operative period. Messenger of Anesthesiology and Resuscitation. 2018;15(1):46–54; Burne-Taney MJ, Liu M, Ascon D, Molls RR, Racusen L, Rabb H. Transfer of lymphocytes from mice with renal ischemia can induce albuminuria in naive mice: a possible mechanism linking early injury and progressive renal disease? Am J Physiol Renal Physiol. 2006;291(5):F981-6. https://doi.org/10.1152/ajprenal.00229.2005; Попов С. В., Гусейнов Р. Г., Скрябин О. Н., Сивак К. В. Тепловая ишемия почки. М., 2021.; Митциев А. К. Изменение активности перекисного окисления липидов как механизм развития патологии почек при действии тяжелых металлов. Патологическая физиология и экспериментальная терапия. 2015;2:72–76.; Balzer MS, Doke T, Yang YW, Aldridge DL, Hu H, Mai H, et al. Single-cell analysis highlights differences in druggable pathways underlying adaptive or fibrotic kidney regeneration. Nat Commun. 2022 Jul 11;13(1):4018. https://doi.org/10.1038/s41467-022-31772-9; Liu Y, Wang J. Ferroptosis, a Rising Force against Renal Fibrosis. Oxid Med Cell Longev. 2022 Oct 12;2022:7686956. https://doi.org/10.1155/2022/7686956; Zhou RP, Chen Y, Wei X, Yu B, Xiong ZG, Lu C, et al. Novel insights into ferroptosis: Implications for age-related diseases. Theranostics. 2020;10(26):11976–11997. https://doi.org/10.7150/thno.50663; Тимербулатов Ш. В., Тимербулатов М. В., Султанбаев А. У. Реперфузионный синдром в абдоминальной хирургии. Медицинский вестник Башкортостана. 2010;5(4):145–151.; Cho A, Lee JE, Kwon GY, Huh W, Lee HM, Kim YG, Kim DJ, Oh HY, Choi HY. Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy. Nephrol Dial Transplant. 2011 Nov;26(11):3496–3501. https://doi.org/10.1093/ndt/gfr094; Lameire N, Vanholder R, Van Biesen W, Benoit D. Acute kidney injury in critically ill cancer patients: an update. Crit Care. 2016 Aug 2;20(1):209. https://doi.org/10.1186/s13054-016-1382-6; Grams ME, Sang Y, Coresh J, Ballew S, Matsushita K, Molnar MZ, et al. Acute Kidney Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data. Am J Kidney Dis. 2016;67(6):872–880. https://doi.org/10.1053/j.ajkd.2015.07.022; Meersch M, Schmidt C, Zarbock A. Perioperative Acute Kidney Injury: An Under-Recognized Problem. Anesth Analg. 2017;125(4):1223–1232. https://doi.org/10.1213/ane.0000000000002369; Djordjevic A, Susak S, Velicki L, Antonic M. Acute Kidney Injury after Open-Heart Surgery Procedures. Acta Clin Croat. 2021;60(1):120–126. https://doi.org/10.20471/acc.2021.60.01.17; Antonelli A, Allinovi M, Cocci A, Russo GI, Schiavina R, Rocco B, et al. The Predictive Role of Biomarkers for the Detection of Acute Kidney Injury After Partial or Radical Nephrectomy: A Systematic Review of the Literature. Eur Urol Focus. 2020;6(2):344–353. https://doi.org/10.1016/j.euf.2018.09.020; Martini A, Sfakianos JP, Paulucci DJ, Abaza R, Eun DD, Bhandari A, et al. Predicting acute kidney injury after robot-assisted partial nephrectomy: Implications for patient selection and postoperative management. Urol Oncol. 2019 Jul;37(7):445–451. https://doi.org/10.1016/j.urolonc.2019.04.018; Wu Y, Chen J, Luo C, Chen L, Huang B. Predicting the risk of postoperative acute kidney injury: development and assessment of a novel predictive nomogram. J Int Med Res. 2021 Aug;49(8):3000605211032838. https://doi.org/10.1177/03000605211032838; Матвеев В. Б. Клиническая онкоурология. М., 2011.; Мосоян М., Румянцев А., Есаян А., Земченко А. Отдаленные результаты открытой, лапароскопической и робот-ассистированной резекции почки. Врач. 2017;28(11):79–82.; Смирнов А. В., Румянцев А. Ш. Острое повреждение почек. Часть I. Нефрология. 2020;24(1):67–95. https://doi.org/10.36485/1561-6274-2020-24-1-67-95; Arthur JM, Hill EG, Alge JL, Lewis EC, Neely BA, Janech MG, et al. Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery. Kidney Int. 2014;85(2):431–438. https://doi.org/10.1038/ki.2013.333; Смирнова Н. Н., Галкина О. В., Новикова В. П., Прокопьева Н. Э. Современные биомаркеры повреждения почек в педиатрии. Нефрология. 2019;23(4):112–118. https://doi.org/10.24884/1561-6274-2019-23-4-112-118; Vijayan A, Faubel S, Askenazi DJ, Cerda J, Fissell WH, Heung M, et al. American Society of Nephrology Acute Kidney Injury Advisory G. Clinical Use of the Urine Biomarker [TIMP-2] x [IGFBP7] for Acute Kidney Injury Risk Assessment. Am J Kidney Dis. 2016;68(1):19–28. https://doi.org/10.1053/j.ajkd.2015.12.033; Димитриади С. Н., Франциянц Е. М., Ушакова Н. Д., Розенко Д. А., Величко А. В Биомаркеры в диагностике острого повреждения почек после органосохраняющего хирургического лечения локализованного рака почки. Медицинский вестник Юга России. 2018;9(3):77–83. https://doi.org/10.21886/2219-8075-2018-9-3-77-83.; Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A, Group NM. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54(6):1012–1024. https://doi.org/10.1053/j.ajkd.2009.07.020; Prowle JR, Kirwan CJ, Bellomo R. Fluid management for the prevention and attenuation of acute kidney injury. Nat Rev Nephrol. 2014;10(1):37–47. https://doi.org/10.1038/nrneph.2013.232; Raimundo M, Crichton S, Martin JR, Syed Y, Varrier M, Wyncoll D, et al. Increased Fluid Administration After Early Acute Kidney Injury is Associated with Less Renal Recovery. Shock. 2015;44(5):431–437. https://doi.org/10.1097/shk.0000000000000453; Кит О. И., Франциянц Е. М., Димитриади С. Н., Каплиева И. В., Трепитаки Л. К., Черярина Н.Д. Роль маркеров острого повреждения почек в выборе тактики хирургического лечения больных раком почки. Онкоурология. 2015;11(3):34–39. https://doi.org/10.17650/1726-9776-2015-11-3-34-39; Eggener SE, Clark MA, Shikanov S, Smith B, Kaag M, Russo P, et al. Impact of warm versus cold ischemia on renal function following partial nephrectomy. World J Urol. 2015 Mar;33(3):351–357. https://doi.org/10.1007/s00345-014-1315-4; Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009 Sep;182(3):844–853. https://doi.org/10.1016/j.juro.2009.05.035; Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB et al. National comprehensive cancer n. Kidney cancer, version 3. 2015. J Natl Compr Canc Netw. 2015;13(2):151–159. https://doi.org/10.6004/jnccn.2015.0022; https://www.rpmj.ru/rpmj/article/view/888

الاتاحة: https://www.rpmj.ru/rpmj/article/view/888
https://doi.org/10.17709/2410-1893-2023-10-2-10

المؤلفون: S. V. Popov, R. G. Guseynov, I. N. Orlov, V. V. Khizha, A. V. Yazenok, K. V. Sivak, V. V. Perepelitsa, N. S. Bunenkov, A. S. Ulitina, С. В. Попов, Р. Г. Гусейнов, И. Н. Орлов, В. В. Хижа, А. В. Язенок, К. В. Сивак, В. В. Перепелица, Н. С. Буненков, А. С. Улитина

المصدر: Cancer Urology; Том 19, № 3 (2023); 163-174 ; Онкоурология; Том 19, № 3 (2023); 163-174 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: статистика здравоохранения, morbidity, mortality, treatment, health statistics, заболеваемость, смертность, лечение

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1653/1489; Gray R.E., Harris G.T. Renal cell carcinoma: diagnosis and management. Am Fam Physician 2019;99(3):179–84.; Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.; Tahbaz R., Schmid M., Merseburger A.S. Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr Opin Urol 2018;28(1):62–79. DOI:10.1097/MOU.0000000000000454; Носов А.К., Лушина П.А. Анализ заболеваемости и смертности от рака почки в России и Санкт-Петербурге. Сибирский онкологический журнал 2017;16(5):95–103. DOI:10.21294/1814-4861-2017-16-5-95-103; Мерабишвили В.М. Злокачественные новообразования в Санкт-Петербурге. СПб., 2015. 295 c.; Capitanio U., Bensalah K., Bex A. et al. Epidemiology of renal cell carcinoma. Eur Urol 2019;75(1):74–84. DOI:10.1016/j.eururo.2018.08.036; Состояние онкологической помощи населению России в 2016 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2017. 236 с.; Состояние онкологической помощи населению России в 2017 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 236 с.; Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.; Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 236 с.; Состояние онкологической помощи населению России в 2020 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 239 с.; Мерабишвили М.В. Онкологическая статистика (традиционные методы, новые информационные технологии). Руководство для врачей. 2-е изд., доп. Часть I. СПб., 2015. 223 с.; Harrison H., Thompson R.E., Lin Z. et al. Risk prediction models for kidney cancer: a systematic review. Eur Urol Focus 2021;7(6):1380–90. DOI:10.1016/j.euf.2020.06.024; Гаас М.Я., Каприн А.Д., Воробьев Н.В. и др. Предикторы местного рецидива рака почки. Наш опыт. Сибирский онкологический журнал 2022;21(4):16–24. DOI:10.21294/1814-4861-2022-21-4-16-24; Cheung D., Frankel J., Tut P. et al. Treatment on active surveillance of small renal masses: progression vs. preference. Can Urol Assoc J 2022;16(4):97–101. DOI:10.5489/cuaj.7451; Попов С.В., Гусейнов Р.Г., Орлов И.Н. и др. Оценка качества жизни пациентов после хирургического лечения рака почки. Онкоурология 2019;15(2):25–34. DOI:10.17650/1726-9776-2019-15-2-25-34; https://oncourology.abvpress.ru/oncur/article/view/1653

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1653
https://doi.org/10.17650/1726-9776-2023-19-3-163-174

المؤلفون: S. V. Popov, R. G. Guseynov, V. V. Khizha, A. V. Yazenok, K. V. Sivak, E. V. Pomeshkin, V. V. Perepelitsa, N. S. Bunenkov, T. A. Lelyavina, С. В. Попов, Р. Г. Гусейнов, В. В. Хижа, А. В. Язенок, К. В. Сивак, Е. В. Помешкин, В. В. Перепелица, Н. С. Буненков, Т. А. Лелявина

المصدر: Cancer Urology; Том 19, № 2 (2023); 133-145 ; Онкоурология; Том 19, № 2 (2023); 133-145 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: статистика здравоохранения, morbidity, mortality, diagnosis, treatment, health statistics, заболеваемость, смертность, диагностика, лечение

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1684/1466; Witjes J.A., Babjuk M., Bellmunt J. et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort (dagger): under the auspices of the EAU-ESMO Guidelines Committees. Eur Urol 2020;77(2):223–50. DOI:10.1016/j.eururo.2019.09.035; Teoh J.Y., Huang J., Ko W.Y. et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol 2020;78(6):893–906. DOI:10.1016/j.eururo.2020.09.006; Wong M.C.S., Fung F.D.H., Leung C. et al. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep 2018;8:1129. DOI:10.1038/s41598-018-19199-z; Van Osch F.H., Jochems S.H., van Schooten F.J. et al. Quantified relations between exposure to tobacco smoking and bladder cancer risk: A meta-analysis of 89 observational studies. Int J Epidemiol 2016;45(3):857–70. DOI:10.1093/ije/dyw044; Cumberbatch M.G.K., Jubber I., Black P.C. et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 2018;74(6):784–95. DOI:10.1016/j.eururo.2018.09.001; Purdue M.P., Hutchings S.J., Rushton L., Silverman D.T. The proportion of cancer attributable to occupational exposures. Ann Epidemiol 2015;25(3):188–92. DOI:10.1016/j.annepidem.2014.11.009; Состояние онкологической помощи населению России в 2012 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2013. 232 с.; Состояние онкологической помощи населению России в 2013 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2014. 235 с.; Состояние онкологической помощи населению России в 2014 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2015. 236 с.; Состояние онкологической помощи населению России в 2015 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2016. 236 с.; Состояние онкологической помощи населению России в 2016 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2017. 236 с.; Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 250 с.; Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 с.; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.; Карякин О.Б. Рак мочевого пузыря: что нового в 2020–2021 гг. Онкоурология 2021;17(4):115–23. DOI:10.17650/1726-9776-2021-17-4-115-123; Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.; Белякова Л.И., Шевченко А.Н., Сагакянц А.Б., Филатова Е.В. Маркеры рака мочевого пузыря: их роль и прогностическая значимость (обзор литературы). Онкоурология 2021;17(2):145–56. DOI:10.17650/1726-9776-2021-17-2-145-156; Zlotta A.R., Roumeguere T., Kuk C. et al. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. Eur Urol 2011;59(6):1026–31. DOI:10.1016/j.eururo.2011.03.027; Dobruch J., Oszczudłowski M. Bladder cancer: current challenges and future directions. Medicina (Kaunas) 2021;57(8):749. DOI:10.3390/medicina57080749; https://oncourology.abvpress.ru/oncur/article/view/1684

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1684
https://doi.org/10.17650/1726-9776-2023-19-2-133-145

المؤلفون: S. V. Popov, R. G. Guseynov, I. N. Orlov, K. V. Sivak, O. N. Skryabin, V. V. Perepelitsa, A. S. Katunin, S. Yu. Yasheva, A. S. Zaytsev, С. В. Попов, Р. Г. Гусейнов, И. Н. Орлов, К. В. Сивак, О. Н. Скрябин, В. В. Перепелица, А. С. Катунин, С. Ю. Яшева, А. С. Зайцев

المساهمون: The study was performed without external funding., Исследование проведено без спонсорской поддержки.

المصدر: Cancer Urology; Том 18, № 4 (2022); 42-55 ; Онкоурология; Том 18, № 4 (2022); 42-55 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: онкологический результат, surgical treatment, laparoscopic radical prostatectomy, expanded pelvic lymphadenectomy, functional results, oncological results, хирургическое лечение, лапароскопическая радикальная простатэктомия, расширенная тазовая лимфаденэктомия, функциональный результат

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1569/1415; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.; Грицкевич А.А., Медведев В.Л., Костин А.А., Русаков И.Г. Прогностические факторы выживаемости больных при раке предстательной железы. Экспериментальная и клиническая урология 2017;(4):12–9. DOI:10.29188/2222-8543; Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 236 с.; Маслякова Г.Н., Воронина Е.С., Фомкин Р.Н. Морфологические методы исследования в диагностике рака предстательной железы. Фундаментальные исследования 2012;(12 (часть 2)):426–30.; Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Российской Федерации. Экспериментальная и клиническая урология 2011;(2–3):6–7.; Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2013. 289 с.; Переверзев А.С., Илюхин Ю.А. Тактика лечения локальнораспространенного (Т3) рака простаты. Актуальные вопросы диагностики и лечения рака предстательной железы: материалы международной научно-практической конференции, 27–28 октября 2006 г. Минск, 2006.; Heidenreich A., Pfister D., Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 2015;193(3):832–8. DOI:10.1016/j.juro.2014.09.089; Amiya Y., Yamada Y., Sugiura M. et al. Treatment of locally advanced prostate cancer (Stage T3). Jpn J Clin Oncol 2017;47(3):257–61. DOI:10.1093/jjco/hyw186; Рак предстательной железы: взаимодействие урологов и онкологов. Учебно-методические рекомендации № 80. И.Е. Хатьков, Д.Ю. Пушкарь, А.В. Говоров и др. М.: АБВ-пресс, 2018. 46 с.; Dearnaley D.P., Sydes M.R., Langley R.E. et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol 2007;83(1):31–41. DOI:10.1016/j.radonc.2007.02.014; Heemsbergen W.D., Al-Mamgani A., Slot A. et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 2014;110(1):104–9. DOI:10.1016/j.radonc.2013.09.026; Clinical Guidelines. European Association of Urology, 2020.; EAU Guidelaines. Presented at the EAU Annual Congress, Amsterdam, Netherlands, 2020.; Алексеев Б.Я., Крашенинников А.А., Нюшко К.М. и др. Хирургическое лечение больных раком предстательной железы с высоким риском прогрессирования: отдаленные онкологические результаты и факторы прогноза. Онкоурология 2020;16(4):99–111. DOI:10.17650/1726-9776-2020-16-4-99-111; Крашенинников А.А., Сергиенко С.А., Алексеев Б.Я. и др. Результаты хирургического лечения больных раком предстательной железы (РПЖ) с высоким риском прогрессирования. I Национальный конгресс «Онкология репродуктивных органов: от профилактики и раннего выявления к эффективному лечению», 2016.; Лоран О.Б., Велиев Е.И., Котов С.В. Онкологические результаты радикального хирургического лечения пациентов с местно-распространенным раком предстательной железы. Онкоурология 2009;5(3):29–34. DOI:10.17650/1726-9776-2009-5-3-29-34; Stewart S.B., Boorjian S.A. Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. Urol Oncol 2015;33(5):235–44. DOI:10.1016/j.urolonc.2014.10.003; Nazim S.M., Abbas F. Role of Surgery in locally advanced prostate cancer. Pak J Med Sci 2015; 31(3):710–6. DOI:10.12669/pjms.313.7103; Попков В.М., Ким Т.Д., Понукалин А.Н. Диагностика и комбинированное лечение больных с местно-распространенным раком простаты (обзор). Саратовский научно-медицинский журнал 2015;11(3):317–22.; Hsu C.Y. Outcome of surgery for clinical unilateral T3a prostste cancer: a single-institution experience. Eur Urol 2007;51(1):121–8. DOI:10.1016/j.eururo.2006.05.024; Retel V.P., Bouchardy C., Usel M. et al. Determinants and effects of positive surgical margins after prostat-ectomy on prostate cancer mortality: a population-based study. BMC Urol 2014;14:86. DOI:10.1186/1471-2490-14-86; Ward J.F. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95(6):751–6. DOI:10.1111/j.1464-410X.2005.05394.x; Морозов А.О. Результаты хирургического лечения больных раком простаты высокого риска прогрессии. Дис. … канд. мед. наук. М., 2019.; Нюшко К.М., Перепухов В.П., Козлова П.С. и др. Сравнение эффективности лапароскопической и открытой радикальной простатэктомии: объединенный анализ результатов лечения больных раком предстательной железы в 3 федеральных центрах. Онкоурология 2021;17(1):45–53. DOI:10.17650/1726-9776-2021-17-1-45-53; Перлин Д.В., Александров И.В., Зипунников В.П., Попова М.Б. Лапароскопическая нероботическая радикальная экстраперитонеальная эндофасциальная простатэктомия. Кремлевская медицина. Клинический вестник 2017;(2):33–9.; Перепечай В.А., Васильев О.Н. Лапароскопческая радикальная простатэктомия. Вестник урологии 2018;6(3):57–72. DOI:10.21886/2308-6424-2018-6-3-57-72; Gregory A., Simonado A., Lissiani A. et al. Laparoscopic radical prostatectomy: perioperative complications in an initial and consecutive series of 80 cases. Eur Urol 2003;44(2):190–4. DOI:10.1016/s0302-2838(03)00261-6; Волченко Н.Н., Каприн А.Д., Беляков М.М., Петров А.Н. Сравнительный анализ степени дифференцировки рака предстательной железы на биопсийном и операционном материалах. Онкология. Журнал им. П.А. Герцена 2016;5(1):18–22. DOI:10.17116/onkolog20165118-22; Brockman J.A., Alanee S., Vickers A.J. et al. Nomogram predicting prostate cancer-specific morta-lity for men with biochemical recurrence after radical prostatectomy. Eur Urol 2015;67(6):1160–7. DOI:10.1016/j.eururo.2014.09.019; Joniau S., Briganti A., Gontero P. et al. Stratification of high-risk prostate cancer into prognostic categories: a European multiinstitutional study. Eur Urol 2015;67(1):157–64. DOI:10.1016/j.eururo.2014.01.020; Joniau S., Spahn M., Briganti A. et al. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. Eur Urol 2015;67(2):319–25. DOI:10.1016/j.eururo.2014.03.013; Cooperberg M., Carroll P. Trends in management for patients with localized prostate cancer, 1990–2013. JAMA 2015;314(1):80–2. DOI:10.1001/jama.2015.6036; Briganti A., Karnes R.J., Gandaglia G. et al. Natural history of surgically treated high-risk prostate cancer. Urol Oncol 2015;33(4):163. DOI:10.1016/j.urolonc.2014.11.018; Нюшко К.М. Хирургическое и комбинированное лечение у больных первичным и рецидивным раком предстательной железы. Дис. … д-ра мед. наук. М., 2020.; https://oncourology.abvpress.ru/oncur/article/view/1569

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1569
https://doi.org/10.17650/1726-9776-2022-18-4-42-55